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ABSTRACT OF THE DISSERTATION 
Synthesis of a C-Deoxyribonucleoside Modelled on Diaminopyrimidine: Evalu-
ation of its Compatibility with the Modern DNA Alphabet 
 
by 
Caroline Roost 
 
  
University of Zürich, 2012 
Prof. Dr. Jay S. Siegel, Chair 
 
 
From the beginning, mankind has had an interest in understanding who we are and 
from where we come. A chemical approach to answer these questions leads back in time to 
the point where the first living unit formed. Over the years several ideas of possible precur-
sors of today’s form of life have been discussed. Today’s genetic storage material, deoxyri-
bonucleic acid (DNA), consists of two different main groups of monomer units, which are 
pyrimidine- or purine-based nucleosides. According to a hypothesis that will be investi-
gated in this thesis, an all-pyrimidine system existed on the early earth. All four nucleo-
bases involved in the proposed pyrimidine system could have evolved from a single source, 
namely from 2,4-diaminopyrimidine. Simple hydrolysis could then have led to two modern 
pyrimidine bases, cytosine (C) and uracil (U), as well as to two exocyclic amino nucleo-
sides (EAN’s). These two EAN’s are D and E, which are based on 2,4-diamiopyrimidine 
and cytosine, respectively. While D is presumably an analogue of the contemporary purine 
nucleoside adenosine (A), E can mimic guanosine (G). 
In this work, model compounds for EANs were used due to stability reasons. By ex-
changing the exocyclic amino function by a carbon, the stability of these compounds could 
be increased. Homo-C-nucleoside D was successfully synthesised previously, although the 
proposed synthesis showed some drawbacks. The separation of four important intermedi-
ates was only achieved by high performance liquid chromatography (HPLC) separation, 
which is very costly, time-consuming and not suitable for the synthesis of larger amounts of 
material. In this thesis, several different syntheses and optimisations are investigated. The 
most promising synthetic pathway still requires a HPLC purification step. Nevertheless, the 
number of compounds that need to be isolated by HPLC was reduced from four to two. Ad-
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ditionally, the total yield was increased. Furthermore, a successful way to obtain E, which 
could not have been synthesised beforehand, was proposed.  
To investigate the base pairing properties of D, isothermal titration calorimetry (ITC) 
measurements were performed. The enthalpy of duplex formation from complementary oli-
gonucleotide strands with varying middle positions were measured and compared. The re-
sults show a certain selectivity of D for U, suggesting that D is a mimic of A, as formulated 
by the hypothesis. Additionally, in one case, selectivity of D for A is observed. This can be 
explained by rotation of the nucleobase around the methylene bridge of the homo-C-
nucleoside. 
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ZUSAMMENFASSUNG 
Synthesis of a C-Deoxyribonucleoside Modelled on Diaminopyrimidine: Evalu-
ation of its Compatibility with the Modern DNA Alphabet 
 
von 
Caroline Roost 
  
Universität Zürich, 2012 
Prof. Dr. Jay S. Siegel, Vorsitz 
 
 
Seit jeher hat sich die Menschheit dafür interessiert, wer wir sind und woher wir 
kommen. Chemiker versuchen dieser Frage nachzugehen indem sie den Zeitpunkt, an dem 
die erste lebende Einheit entstand, erforschen. Über die Jahre wurden verschiedene mögli-
che Vorläufer unserer heutigen Lebensform diskutiert. Die heutige Erbsubstanz, Deoxyri-
bonukleinsäuren (DNS), besteht aus zwei verschiedenen Arten von Einzeleinheiten. Dies 
sind Pyrimidine- oder Purin-basierte Nukleoside. Einer Hypothese folgend, welche in dieser 
Doktorarbeit eingehend untersucht wird, existierte einst ein genetischer Code, welcher nur 
aus Pyrimidine-Nukleosiden bestand. Alle vier Nukleobasen, welche in diesem vorgeschla-
genen Pyrimidinsystem existierten, könnten von einer gemeinsamen Quelle abstammen, 
nämlich 2,4-Diaminopyrimidin. Durch Hydrolyse bildeten sich dann die heute vorkom-
menden Pyrimidinbasen Cytosin (C) und Uracil (U) und zudem zwei exozyklische Amino-
nukleoside (EANs). Diese beiden EANs sind D und E, welche auf 2,4-Diaminopyrimidin 
bzw. Cytosin basieren. D ist ein Analog von Adenosin (A), während E ein Analog von 
Guanosin (G) ist. 
Aus Stabilitätsgründen wurde in dieser Arbeit mit Modelverbindungen für die EANs 
gearbeitet. Durch Austausch des exozyklischen Stickstoffs mit Kohlenstoff konnte die Sta-
bilität dieser Verbindungen erhöht werden. Homo-C Nukleosid D konnte vorgängig bereits 
erfolgreich hergestellt werden, aber die vorgeschlagene Synthese hatte einige Nachteile. 
Die Trennung von vier wichtigen Zwischenstufen konnte nur mittels Hochleistungs-
Flüssigchromatographie (HPLC) erreicht werden. Diese Methode ist sehr teuer, zeitintensiv 
und ungeeignet für grössere Mengen von Material. In der vorliegenden Arbeit wurden meh-
rere verschiedene Synthesen und Optimierungen untersucht. Der aussichtsreichste Pfad 
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braucht immer noch einen HPLC-Reinigungsschritt, aber die Anzahl Verbindungen, welche 
per HPLC getrennt werden müssen, konnte von vier auf zwei reduziert werden. Zudem 
konnte die Gesamtausbeute erhöht werden. Ausserdem wurde ein Weg zur Synthese von E 
gefunden, welches vorgängig nicht hergestellt werden konnte. 
Zur Untersuchung der Eigenschaften zur Basenpaarung von D wurden isothermale 
Titrationskalorimetrie-Messungen (ITC) durchgeführt. Die Enthalpie der Duplexausbildung 
von komplementären Oligonukleotidsträngen mit variabler Mittelposition wurde gemessen 
und die Resultate miteinander verglichen. Die Auswertung zeigt eine gewisse Selektivität 
von D für U. Dies lässt darauf schliessen, dass D ein Analog von A ist, wie es die unter-
suchte Hypothese besagt. Zudem kann in einem Fall eine Selektivität von D für A beobach-
tet werden. Dies kann mit einer Drehung der Nukleobase um die Methylbrücke des Homo-
C Nukleosids erklärt werden. 
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1 Introduction 
1.1 Origin of Life 
Ever since the beginning of time, humans have had an interest in understanding where 
we come from and, consecutively, who we are. The first attempts to address those questions 
were of philosophical nature. Over the past few decades, chemists started to take an interest in 
the questions concerning life and began postulating how the very first life on earth formed, 
referring to this time as the origin of life. To address these questions about life, a definition of 
the term “life” is needed but opinions differ highly on this question. The most rudimentary 
definition of a “living unit” requires the capability of reproduction, therefore including a sys-
tem that stores and transmits genetic information. In all present-day organisms, except for 
some viruses, this storage system of genetic information is deoxyribonucleic acid (DNA).1 
There are two main questions in the field of origin of life chemistry. The first question 
asks which biopolymer was first, DNA, ribonucleic acid (RNA) or peptides, and from which 
precursor it evolved. The second question centres around the problem of compartmentalisa-
tion, meaning the organisation of a living unit in different compartments and the transmission 
of genetic material from one compartment to an other. In this project, manly the first question 
about the precursor of the first biopolymer is addressed. 
One big difficulty in finding answers regarding the origin of life is the fact that we can-
not be sure about the conditions found on the prebiotic earth. Generally, a moderate pH and 
aqueous environment is assumed. Miller and Urey proposed that the earth started with a re-
ducing atmosphere that became later oxidising due to the escape of hydrogen.2 The largest 
source of uncertainty in this prebiotic atmosphere is the temperature. A hydrothermal envi-
ronment with up to 100 °C has been proposed due to the fact that thermophilic microorgan-
isms, which grow at elevated temperatures, are found to be the oldest known organisms to 
date.3 Other experts like Bada and Lazcano have an opposite theory. They assume that a low 
temperature environment existed due to the instability of biomolecules at high temperatures 
and the fact that mineral-based concentration of molecules, involving weak noncovalent 
bonds, is most effective at low temperatures.4 
Regardless of the exact conditions at this time on Earth, the primordial soup theory is 
nonetheless widely accepted. Independently developed by Oparin and Haldane5 in the 1920s, 
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a modern version of the theory states that organic compounds accumulated in the primordial 
oceans and underwent polymerisation, thereby produced complex macromolecules that even-
tually developed the ability to catalyse their own replication, thus leading to the origin of life, 
the RNA world and finally to today’s DNA/RNA/Protein system (Figure 1.1). 
 
 
Figure 1.1: Various steps from the formation of the primordial soup to the origin of life on 
the early earth.
4 
 
1.1.1 Historical Overview 
Present models state that the formation of the earth began approximately 4.5 billion 
years ago and that the first living organisms, prokaryotic microfossils, are around 3.6 billion 
years old.6,7 Between these two mile stones lies the time interval of prebiotic chemistry, fol-
lowed by the RNA world, that will be described in Section 1.1.2. 
An important impulsion in the field of prebiotic chemistry was the famous experiment 
by Miller and Urey in 1953.2,8 Based on the primordial soup theory, the researchers mimicked 
the atmosphere on the early Earth by exposing CH4, NH3, H2O and H2 to an electric discharge 
in a closed circular system (Figure 1.2) and they were able to isolate amino acids in the milli-
gram range. For a long time after this experiment, it was believed that proteins were the first 
biopolymers on earth and therefore the prebiotic hereditary material. This assumption was 
based on the results of the Miller-Urey experiment, where amino acids were synthesised 
under presumably prebiotic conditions, as well as based on the fact that proteins have been 
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known to possess catalytic activities. Often, a co-existence of proteins and RNA was as-
sumed, with the latter holding the genetic information.9 
 
Figure 1.2: Experimental setup of the Urey-Miller experiment.
8
 
 
It was not until the 1980s, when both, Cech and co-workers and Altman and co-workers 
independently found that RNA exhibited catalytic activities. Altman and his team worked 
with Escherichia coli and found that ribonuclease-P cleaves phosphodiester bonds during the 
maturation of the transfer RNA (tRNA) molecule.10,11 Cech et al. discovered that the riboso-
mal RNA (rRNA) of Tetrahymena contained a self-splicing exon.12,13 In 1989, Cech and Alt-
man were jointly awarded the Nobel Prize in Chemistry for their discovery of catalytic prop-
erties of RNA. From this discovery, RNA appeared to be the long-sought piece that combines 
the ability to store genetic information while presumably catalysing its own replication. Prior 
to this discovery it had been speculated that RNA is both the original genetic as well as cata-
lytic material14,15 but only the finding of the catalytic properties of RNA opened the way for 
the RNA world hypothesis, which will be described in detail in the following section. 
 
1.1.2 RNA World 
The RNA-world hypothesis is currently the most accepted theory of the origin of 
biopolymers and life, even it is solely based on indications. The hypothesis states that at the 
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beginning of chemical evolution there were only RNA molecules, since RNA provided all of 
the functions needed for the first biopolymers to evolve: providing genetic information and 
serving to catalyse the synthesis of themselves.16 Furthermore, it is the connection between 
DNA and proteins, thus between genetic material and metabolism. According to the RNA-
world hypothesis, at the first stage of chemical evolution, RNA performed the catalytic activi-
ties to assemble themselves from the primordial soup. By using recombination and mutation, 
they could developed new functions and adapt to new niches. Using RNA cofactors then have 
led to an entire range of enzymatic activities.14 Later, RNA started to synthesise proteins, first 
by developing RNA adapters that bound amino acids and then by arranging them according to 
an RNA template using other RNA molecules. This process provided the first proteins, which 
were able to carry out the same enzymatic reactions like RNA but more rapidly and more ef-
fectively. At the next stage DNA appeared, presumably copied from the RNA molecules by 
reverse transcription. With double-stranded DNA, a stable genetic information store was 
formed that possessed error-correcting properties because of its double-stranded structure but 
was still capable of mutation and recombination.9 Following the widely accepted RNA-world 
hypothesis, that is how the present genetic apparatus has evolved. 
To accept that RNA might have been the primordial hereditary material, one should be 
able to show its synthesis under prebiotic conditions. This challenge was not fulfilled until 
Oró published a purine synthesis under prebiotic conditions. As a key intermediate, Oró used 
hydrogen cyanide, a reagent that was also isolated in the Miller-Urey experiment.17 The pre-
biotic synthesis of pyrimidine turned out to be more difficult than purine. The first synthesis 
of cytosine was proposed by Orgel and his team. They were able to synthesise cytosine under 
prebiotic conditions from cyanoethylene and cyanate but only in very poor yields.18  Despite 
several optimisation attempts the yields could not be remarkably improved.19 Several decades 
later, Robertson and Miller finally managed to synthesise cytosine under prebiotic conditions 
in up to 50 % yield. They used a pathway starting from cyanoacetaldehyde (formed by hy-
drolysis of cyanoacetylene) and let it react with a concentrated urea solution. Uracil is easily 
formed by hydrolysis of cytosine.20 
Even after the synthesis of purine and pyrimidine, an important question was still un-
answered: How did the ribonucleotides form? The most obvious approach would be a con-
densation of the furanose form of ribose and the nucleobase. The problem with this approach 
is that it only works inefficiently in the case of purines21 and simply does not work for py-
rimidines22 due to a kinetic reason (the N1 lone pair of cytosine and uracil is unavailable be-
cause of delocalisation) and, in water, a thermodynamic reason (the equilibrium constant is 
such that hydrolysis of ribonucleoside to pyrimidine and ribose is favoured over condensa-
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tion). It was not until recently, that Sutherland and co-workers proposed a way to synthesise 
pyrimidine ribonucleotides under prebiotic conditions.23 Their elegant synthesis starts from 
cyanamide, cyanoacetylene, glycoaldehyde, glyceraldehyde and inorganic phosphate, which 
are all plausible prebiotic molecules.18,24 The synthetic pathway bypasses free ribose and py-
rimidines and proceeds instead through arabinose amino-oxazoline (Figure 1.3). The synthe-
sis of Sutherland and his team was highly appreciated in the origin of life society and gave 
another boost to the RNA world hypothesis. 
 
Figure 1.3: Pyrimidine ribonucleotide assembly options.
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 If there was a RNA world, there must also have been a time period before, known as 
the pre-RNA world. It is assumed that in this pre-RNA world, living organisms contained a 
backbone different from ribose-phosphate and also bases different from C, G, A and U. RNA 
could then have evolved from these precursors.25 In the next section, such possible precursors 
will be presented. 
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1.1.3 Precursors of present-day DNA/RNA 
Two requirements for a possible precursor of DNA and RNA are that it should be 
stable and synthetically accessible under prebiotic conditions. To find such a progenitor, there 
are three different parts to alter: the sugar moiety, the phosphate backbone and the nucleo-
base. 
The group of Eschenmoser followed the question, ‘why did nature chose ribofuranosyl 
nucleic acids instead of another sugar family’ and studied therefore several sugar modifica-
tions under a prebiotic point of view. The most famous example of such a modification is the 
homo-DNA, bearing a six-membered pyranose ring instead of the present five-membered ri-
bose (Figure 1.4, left).26,27 Presumably due to its higher rigidity, homo-DNA forms stronger 
base pairs than natural DNA but does not cross-pair with natural nucleic acids. Therefore, 
homo-DNA was shown to be especially suitable as molecular beacons.28 Another interesting 
example of sugar modification by Eschenmoser et al. is the "-L-threofuranosyl nucleic acid 
(TNA).29 It contains tetrafuranose instead of D-ribose and is linked in a 3’%2’ manner (Fig-
ure 1.4, middle). Surprisingly, TNA shows strong cross-pairing abilities towards its natural 
counterparts despite their conformational and constitutional differences.  
 
Figure 1.4: Structure of Homo-DNA (left) and TNA (middle) compared to RNA (right). 
 
For backbone modifications, a variety of examples exists. Ueda and co-workers were 
the first to propose an acyclic backbone called glycerol nucleic acid (GNA, shown in Figure 
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1.5, left).30 Later, Orgel et al. found that GNA exhibits stronger Watson-Crick pairing than 
natural DNA or RNA, despite the fact that GNA consists of acyclic three carbon backbone 
units.31 Miller and co-workers proposed another backbone modification. They suggested a 
peptide nucleic acid (PNA), similar to proteins but with bases contained in RNA instead of 
amino acids in the side chains (Figure 1.5, middle). PNA can be synthesised under prebiotic 
conditions.32 The idea of Miller et al. is based on work by Westheimer, who pursued the ques-
tion ‘why does nature chose phosphates for the backbone in nucleic acids?’ and came to the 
conclusion that phosphates meet all of the required conditions and that no alternative is obvi-
ous.33 Usher worked on another interesting question: why does RNA have a 3’,5’ linkage? In 
theory, a linkage through the 2’-OH would be possible but Usher concludes that the 3’,5’ 
linkage serves as a protection against internal strand breakage.34 
 
Figure 1.5: GNA (left) and PNA (middle) compared to RNA (right). 
 
Some examples for the third site of evolutionary modification, the nucleobase, are 
found in literature. Benner et al. expanded the genetic alphabet by proposing several new base 
pairs (Figure 1.6, top).35 This expansion could have led to a greater diversity in structure and 
functionality and therefore greater susceptibility to evolution. The described building blocks 
were not synthesised under prebiotic conditions, though. In contrast, Miller and co-workers 
proposed an urazole based precursor that could be synthesised under early-Earth conditions.36 
Urazole forms hydrogen bonds with adenine (Figure 1.6, bottom), comparable with those of 
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uracil. While uracil is completely unreactive with ribose under mild aqueous conditions, ura-
zole reacts spontaneously with ribose and could therefore have been a precursor of uracil. 
 
Figure 1.6: Alternative base pairs. 
 
In 1988, when the synthesis of pyrimidine nucleosides under prebiotic conditions was 
still unrevealed, Wächtershäuser proposed an all-purine base pairing code.37 His assumption 
was based on the fact that pyrimidines cannot oligomerise onto a complementary template 
without assistance of a polymerase due to their low stacking energies. However, purines with 
their higher stacking energy do oligomerise.38 
A counter hypothesis was proposed by Siegel and Tor.39 They suggested an all-
pyrimidine code with three bases, including 2,4-diamionopyrimidine and the naturally occur-
ring cytosine and uracil. 2,4-diaminopyrimidine can be synthesised under prebiotic conditions 
and by simple hydrolysis, it can form cytosine and uracil. Thus, it fulfils the single source 
criterion. This hypothesis is described in depth in Section 2.1. 
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1.2 DNA Structure 
1.2.1 Historical Overview 
In 1866, Haeckel proposed that the material responsible for hereditary properties is lo-
cated in the nucleus of a cell.40 At that time proteins were considered to contain all hereditary 
traits since it was the only cell material known that showed a sufficient complexity to fulfil 
this task. Three years later, Miescher succeeded in the first isolation of DNA from leukocytes 
of pus, found on discarded surgical bandages.41,42 Throughout his experiments, he noticed that 
a substance precipitated from the solution upon adding acid and dissolved again upon adding 
alkali. What he described was the first crude precipitation of DNA. Miescher named the iso-
lated material nuclein, since he found it in the nuclei of the cells. Later tests by Miescher 
showed that nuclein lacked sulfur but contained a large amount of phosphorus.42 This showed 
the new material to be significantly different from proteins. Boveri postulated in 1902, that 
the hereditary units were located on chromosomes43 and seven years later, Johannsen termed 
these hereditary units genes.44 In 1928, Griffith postulated the transforming principle.45 He 
discovered that injection of a mixture of heat-killed virulent S pneumococci (Diplococcus 
pneumoniae) and non-pathogenic R pneumococci in mice resulted in death of a majority of 
the mice. Since S pneumococci were found in the blood of the dead mice, Griffith concluded 
that a transformation of the R to the S form occurred, induced by the heat-killed S pneumo-
cocci. Levene identified the four building blocks of DNA, including the four bases adenine, 
cytosine, guanine and thymine.46,47 Since he found all four bases in an equal ratio, he pro-
posed the tetranucleotide hypothesis, postulating a monotonously repeating sequence (Figure 
1.7), which was therefore not suspected to have any genetic function. 
 
Figure 1.7: Hypothetical tetranucleotide structure. 
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In 1944, Avery, MacLeod and McCarty demonstrated that Griffith’s transforming prin-
ciple is DNA.48 They showed this transforming principle to be unaffected by enzymes that 
catalyse the hydrolysis of proteins and RNA, such as trypsin and ribonuclease, but to be com-
pletely inactivated by DNase. Additionally, the transforming principle showed all the physical 
and chemical properties of DNA but contained no detectable protein. At the end of the 1940s, 
Chargaff determined that within a species, the bases in DNA were always present in fixed 
ratios and he could thereby refute the tetranucleotide hypothesis and at the same time, indi-
cated that DNA could have a sufficient complexity for fulfilling the requirements of a genetic 
material.49  
The structure of DNA was finally revealed in the 1950s. Franklin and Wilkins demon-
strated the regularly repeating helical structure of DNA based on X-ray analyses.50,51 With 
help of this X-ray analyses, Watson and Crick proposed in 1953 the molecular structure of 
DNA to be a double helix in which adenosine always pairs with thymidine and cytidine al-
ways pairs with guanosine.52 An additional important milestone in the history of DNA re-
search was the development of Polymerase Chain Reaction (PCR) by Mullis in 1983, which 
eased the synthesis of DNA enormously and allowed the production of large amounts of DNA 
in a short time.53 Finally, in 1990, the sequencing of the human genome begun and it took 
over a decade, until 2001, when the complete sequence could finally be published.54 Today, a 
lot of different functions of DNA are known. It not only holds the central role in storage and 
expression of genetic information but nucleosides and nucleotides also participate in many 
biochemical processes, like energy-releasing pathways and enzymatic reactions.1 
 
1.2.2 Nucleosides and Nucleotides 
Nucleosides are the monomer units of nucleic acid. Nucleotides are the phosphate es-
ters of nucleosides. They consist of three main parts: a sugar moiety, a nucleobase and a 
phosphate group (Figure 1.8). 
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Figure 1.8: Three main components of nucleic acids: base, sugar and phosphate. 
 
The nucleobase is a nitrogen-containing heterocyclic base, either a purine in the case of 
adenine and guanine or a pyrimidine in the case of cytosine, uracil and thymine. The two pur-
ine bases as well as the pyrimidine base cytosine are found as nucleobases in both RNA and 
DNA. The fourth base occurring in RNA is uracil, while in DNA it is thymine (5-
methyluracil). Figure 1.9 shows the structure of the five bases. 
 
Figure 1.9: Chemical structure and numbering of the nucleobases. 
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The nucleosides are named after the corresponding nucleobase that they contain (Fig-
ure 1.10). In the case of adenosine (A) and guanosine (G), the N9 is linked to the C1’ of the 
pentose, while for cytidine (C), uridine (U) and thymidine (T), it is the N1 that is linked to the 
C1’ of the sugar. This linkage is called the glycosidic bond. In naturally occurring RNA and 
DNA, it is in its #-configuration, meaning that the glycosidic bond is on the same side of the 
sugar like the C4’-C5’ bond. If these two bonds are on opposite sides of the sugar, the con-
figuration is a "-configuration. 
 
Figure 1.10: Chemical structure and numbering of nucleosides. 
 
The sugar moiety is a pentose sugar, D-ribose in the case of RNA and 2-deoxy-D-ribose 
in the case of DNA. With deoxyribose, the name of the nucleoside changes for example in the 
case of adenosine to deoxyadenosine (see Table 1.1). The pentose sugar is locked in a five-
membered ring. 
The phosphate group can be bonded to the C5’-hydroxygroup (5’-nucleotide) or to the C3’-
hydroxygroup (3’-nucleotide). The name changes then for example from adenosine to 
adenylic acid (see Table 1.1).55 
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Symbol Base Nucleoside Nucleotide 
Ribonucleosides and -nucleotides 
A Adenine Adenosine Adenylic acid 
G Guanine Guanosine Guanylic acid 
C Cytosine Cytidine Cytidylic acid 
U Uracil Uridine Uridylic acid 
    
Deoxyribonucleosides and -nucleotides 
A Adenine Deoxyadenosine Deoxyadenylic acid 
G Guanine Deoxyguanosine Deoxyguanylic acid 
C Cytosine Deoxycytidine Deoxycytidylic acid 
T Thymine Thymidine Thymidylic acid 
Table 1.1: Nomenclature of nucleosides and nucleotides. 
 
1.2.3 Physical Properties 
1.2.3.1 Tautomerism 
In solution, heterocyclic molecules usually exist in a rapid equilibrium of tautomers 
due to hydrogen atoms attached to nitrogen atoms, which are able to migrate to other free ni-
trogens or to keto oxygens within the same molecule.56 The tautomerism mainly depends on 
the electric constant of the solvent and on the pKa of the heteroatoms. In general, the naturally 
occurring bases are predominantly in the keto and amino tautomeric forms with an excess of 
103-106 over the enol and imine forms, respectively.57 This is essential, since uracil and gua-
nine in the enol form simulate cytosine and adenine and cytosine and adenine in the imino 
form may substitute for uracil and guanine (Figure 1.11). This substitution may lead to point 
mutations if not detected by repair enzymes.55 
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Figure 1.11: Keto-enol tautomerism of G and U and amine-imine tautomerism of A and C. 
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1.2.3.2 Protonation (pKa) 
The acid-base behaviour is an important physical characteristic of nucleosides since 
protonation of the nucleobase changes the acceptor/donor abilities and therefore the base pair-
ing properties. Protonation and deprotonation of the base occurs between pH 3 and 10. pKa 
values for bases in ribonucleosides and 2’-deoxyribonucleosides are shown in Table 1.2. 
Compound  pKa 
(Site of protonation) Deoxynucleoside Nucleoside 
Adenin (N1) 3.5 3.5 
Guanin (N7) 2.3 2.1 
             (N1) 9.5 9.6 
Cytosine (N3) 4.2 4.0 
Thymine (N3) 9.7 9.9 
Uracil (N3) 9.5 9.6 
Table 1.2: pKa values of bases in 2’-deoxyribonucleosides and ribonucleosides (298 K).
58
 
 
The site of protonation is in all cases the ring nitrogen, not the exocyclic amino nitrogen. Al-
though the amino nitrogens have greater electron density, the ring nitrogens are more acidic 
due to better stabilisation of the protonated species by resonance.55 The pKa values for the 2’-
hydroxy groups of ribonucleosides A, G, C and U were found to be 12.2, 12.5, 12.5 and 12.6, 
respectively.59 
 
1.2.3.3 Stability 
Stability is a crucial point in origin of life science since for a compound to be used in 
the first living organism it needs to show sufficient stability in order to keep the balance be-
tween synthesis and degradation. A high degradation rate would lead to vanishingly small 
concentrations. Especially the stability at high temperatures is of interest since a high-
temperature-origin of life with temperatures between 80 and 110 °C is widely favoured (see 
Section 1.1). A common source of instability in nucleosides is the nucleobase, especially in 
form of deamination of the base.60 By deamination, guanine can be converted to xanthine, 
adenine to hypoxanthine and cytosine to uracil. Especially the latter is of importance for this 
project. Table 1.3 shows the half-lives of the naturally occurring nucleobases and diaminopy-
rimidine (D) in aq. solution (2.5!10-5 to 1!10-3 M concentration in 0.05 M phosphate buffer; 
pH 7).61 
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Temperature A G C T U D 
0 °C 6.0!105 yr 1.3!106 yr 17 000 yr 2.0!109 yr 3.8!108 yr 40 000 yr 
25 °C 10 000 yr 10 000 yr 340 yr    
100 °C 1 yr 0.8 yr 19 d 56 yr 12 yr 42 d 
Table 1.3: Half-lives of the naturally occurring nucloebases and of diaminopyrimidine. 
 
The most stable bases are thymine and uracil, followed by the purine bases adenine and 
guanine. By far the shortest half-life has cytosine. Even the half-life of 17,000 years at 0 °C is 
very short on a geologic time scale. Because 2,4-diaminopyrimidine is a centrepiece of this 
project, its stability is also discussed here. The half-live of D is comparable to the one of C. It 
can undergo hydrolysis to cytosine and isocytosine and further to uracil (Scheme 1.1).  
 
Scheme 1.1: Hydrolysis of diaminopyrimidine. 
The stability for nucleosides and nucleotides in single stand DNA does not remarkably 
change. The half-life for cytidine in single-stranded DNA is 200 years at 37 °C, which is 
about the same as the free cytosine base. However, in double-stranded DNA the half-life in-
creases to 30,000 years, which is a 150-fold increase. This leads to the conclusion that deami-
nation of the nucloebase is strongly dependent on the environment.62 
Nucleobases are not the only parts of nucleotides that are susceptible to decomposition 
or cleavage. Another vulnerable point of attack is the N-glycosidic bond. Hydrolysis of this 
bond leads to a release of free base. In general, purine nucleotides release their base 20 times 
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faster than pyrimidine nucleotides. Interestingly, the rate of depurination of double-stranded 
DNA is only slowed down four times compared to single-stranded DNA.63 
Another point that should be mentioned here is the difference in stability between RNA 
and DNA. The 2’-OH group of RNA stabilises the N-glycosidic bond. However, it makes the 
phosphodiester bond much more susceptible to hydrolysis (Scheme 1.2), especially in the 
presence of base.64 
 
Scheme 1.2: Hydrolysis of RNA. 
 
1.2.4 Nucleic Acids 
Nucleotide chains containing 20 or less monomer units are called oligonucleotides. Nu-
cleic acids are defined as chains with more than 20 nucleoside units. There are two main 
classes of nucleic acids: ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). They dif-
fer in the sugar moiety, which is a D-ribose in case of RNA and a 2-deoxy-D-ribose in case of 
DNA. 
 
1.2.4.1 Primary Structure 
In natural DNA, the nucleotides are always linked by a phosphodiester bond between 
the 5’-end of one nucleotide to the 3’-end of another. There are no 5’-5’ or 3’-3’ linkages, 
which means that the uniqueness of a DNA primary structure only depends on the sequence 
of its bases.65 
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The sugar-phosphate structure of a nucleotide in a nucleic acid is defined by the torsion 
angles ", #, &, ', ( and ) while the glycosidic bond is described by * (Figure 1.12, left). Des-
pite these numerous torsion angles, nucleic acids are not as flexible as one would imagine. 
The torsion angles are subjected to many intramolecular restraints. For example about the 
glycosidic bond, only two orientations of the base are sterically reasonable: syn and anti. The 
most common is the syn orientation. An exception is Z-DNA, where only pyrimidines are 
found as syn conformers but purines are in anti orientation. The nucleobase plane is almost 
perpendicular to the plane of the sugar. 
Another important conformational description is the sugar pucker. In general, a five-
membered furanose is nonplanar. It can be puckered in an envelope form, which has four 
atoms in a plane and the fifth atom out of plane, or in a twist form with a plane through three 
of the atoms and two adjacent atoms on opposite sides of the plane. Ribose is normally in a 
form between envelope and twist but more towards the twist form. If the C2’ or C3’ sticks out 
of the plane on the same side like the C5’, it is referred to as endo. The other side of the plane 
is called exo. Only two conformations are found in nucleosides: the C2’-endo, also called 
south (S) and the C3’-endo, also called N for north (Figure 1.12, right). A-DNA only contains 
C3’-endo riboses while B-DNA occurs as C2’-endo ribose. In Z-DNA, both forms are found: 
C2’-endo for pyrimidine nucleotides and C3’-endo for purine nucleotides.  
 
Figure 1.12: Torsion angles of a nucleotide unit (left) and the preferred endo sugar puckers 
(right). 
 
1.2.4.2 Secondary Structure 
Three different types of DNA are known: A-DNA, B-DNA and Z-DNA. The X-ray dif-
fraction pattern that Watson and Crick used in 1953 to deduce the helical structure came from 
a B-DNA.52 The A-DNA was discovered in the same year by Franklin and Gosling.66 They 
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also found that B-DNA undergoes a conformational change to A-DNA at a relative humidity 
below 75 % and that this process is reversible. In 1979, Rich and co-workers discovered a 
left-handed form of DNA, the Z-DNA.67 Table 1.4 summarises the structural characteristics 
of A-, B- and Z-DNA. 
 A-DNA B-DNA Z-DNA 
Helical sense Right-handed Right-handed Left-handed 
Diameter +26 Å +20 Å +18 Å 
Base pairs per helical turn 11.6 10 12 (6 dimers) 
Helical twist per base pair 31° 36° 9° (pyrimidine-purine); 
51° (pur-pyr) 
Helix pitch (rise per turn) 34 Å 34 Å 44 Å 
Helix rise per base pair 2.9 Å 3.4 Å 7.4 Å per dimer 
Base tilt normal to helix 
axis 
20° 6° 7° 
Major groove Narrow and 
deep 
Wide and deep Flat 
Minor groove Wide and shal-
low 
Narrow and 
deep 
Narrow and deep 
Sugar pucker C3’-endo C2’-endo C2’-endo for pyrimidines; 
C3’-endo for purines 
Glycosidic bond Anti Anti Anti for pyrimidines; syn 
for purines 
Table 1.4: Characteristics of A-, B- and Z-DNA. 
 
The main factor contributing to duplex stabilisation is stacking. In a nucleic acid strand 
in aqueous solution, bases pile up in stacks similar to coins in a roll. The bases are oriented in 
a way such that one base plane is parallel to the adjacent base. Responsible for the stacking of 
nucleobases are dipole-induced dipole interactions, where a permanent dipole, mainly amino- 
and keto-groups, of one base are superimposed over the ,-electronic system of the adjacent 
base.68 Beside dipole-induced dipole interactions, also London dispersion forces69 and hydro-
phobic forces70 are responsible for base stacking. 
Hydrogen bonds do not play a significant role in duplex stabilisation because of com-
petition of the hydrogen bonds between nucleobases with water. For a long time it was as-
sumed that hydrogen bonding only had a small contribution to duplex stabilisation but was 
essential for specific base pairing and to ensure the fidelity of DNA replication.55 This 
changed with the surprising results in the study by Kool and co-workers.71 In this famous 
work, the authors used 2,4-difluorotoluene (F) as a thymine isostere in a DNA replication ex-
periment (Figure 1.13). Fluorine is no or only a very poor hydrogen bond acceptor, therefore 
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F is, unlike T, not able to form hydrogen bonds. Nevertheless, when F was incorporated in a 
DNA strand, A was efficiently inserted opposite F during replication with almost the same 
efficiency as opposite T. From this work it can be concluded that shape and steric fit are the 
more important factors in the selection of bases during the replication process, and not the 
ability to form hydrogen bonds. 
 
Figure 1.13: Structure of thymidine (T) and 2,4-difluorotoluene (F). 
 
1.2.4.3 Hydrogen Bonding Motifs 
Under the assumption that at least two hydrogen bonds must be formed in order to ob-
tain a stable base-pair, the four bases, when substituted at the glycosyl nitrogen (N1 and N9 
for pyrimidines and purines, respectively), can be arranged in 28 different ways.55 Two of 
them are the Watson-Crick base pairs, the other 26 are mismatches. The most important 
among them are shown in Figure 1.14. 
One arrangement is the Wobble configuration, discovered by Crick in 1966.72 The 
thermodynamic stability of the G-U Wobble base pair is comparable to the Watson-Crick base 
pairs. Furthermore, it is almost isomorphic to them. It can be found in nearly every class of 
RNA.73 
A-T base pairs in solution form Hoogsteen base pairs. They are not found in double 
helices, though. These base pairs were discovered by Hoogsteen in 1963 and can be found in 
nature in tRNA, in triple helices or in G-tetrades, the sub-units of G-quadruplexes (Figure 
1.15).74,75 
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Figure 1.14: Hydrogen bonding motifs.  
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Figure 1.15: G-tetrade, consisting of four guanosines. 
 
1.3 Exocyclic Amino Nucleosides (EANs) 
Several examples of natural or synthetic exocylic amino nucleosides (EANs) are 
known. Formamidopyrimidines can be found in nature. They result from oxidative damage to 
purine nucleosides and are involved in mutagenesis.76 Greenberg and co-workers studied 
Fapy!dA and Fapy!dG, which are degradation products of dA and dG, respectively (Scheme 
1.3).77 
 
Scheme 1.3: Formation of Fapy!dG and Fapy!dA. 
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Another important example of EANs is clitocine (Figure 1.16, left). It is a secondary 
fungal metabolite and acts as an adenosine mimics that shows cytostatic effects towards sev-
eral leukaemia cell lines as well as insecticidal activities.78,79 An example of synthetic EANs 
found in literature are triazine EANs (Figure 1.16, right).80 They will be further discussed in 
the next section in terms of stability.  
 
 
Figure 1.16: Molecular structure of clitocine and triazine EANs. 
 
1.3.1 Stability of EANs 
EANs can undergo acid-induced anomerisation, isomerisation and hydrolysis (cleavage 
of the nucleobase), as can be seen in Scheme 1.4. 
 
 
Scheme 1.4: Mechanism of Isomerisation, Anomerisation and Hydrolysis. 
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Hysell et al. studied several triazine EANs and found that triazine EANs, which contain 
electron rich aromatic rings, are more susceptible for isomerisation and hydrolysis than elec-
tron poor ones. Also, increasing pH and protic solvents increase the rate for all decomposition 
processes.80  
Especially when working with EAN systems affording nucleobases with intermediate 
or high electron density, a way has to be found to avoid anomerisation, isomerisation and 
cleavage of the nucleobase. Greenberg and co-workers used the fact that EANs are more 
stable as dinucleotides than as mononucleotides. Therefore, they synthesised a dinucleotide-
phosphoramidite as starting point for the DNA chain growth. With their approach, Greenberg 
and his team were only able to incorporate an anomeric mixtures of Fapy!dG and Fapy!dA but 
no anomeric pure compounds.81 
Another approach has also been described by Greenberg and co-workers. In this ap-
proach, the exocylic nitrogen that forms the glycosidic bond is exchanged with a carbon.81 
This increases the stability of the glycosidic bond and allows for an insertion of a defined 
anomer in pure form into an oligonucleotide strand. Greenberg and his group could show by 
molecular modelling82 as well as experimentally81 by duplex melting studies that homo-C 
analogues, modelled on Fapy!dG and Fapy!dA, are suitable models for the formamidopyrimi-
dine lesion. Generally, a C-nucleoside is defined as a nucleoside with a C-C glycosidic bond 
instead of the naturally occurring C-N glycosidic bond. A subclass of C-nucleosides are 
homo-C-nucleosides. Their sugar moiety is connected by a methylene bridge to a carbon atom 
of the nucleobase.83 
A third approach by Carell and team strengthens the glycosidic bond by replacement of 
the furanose sugar moiety by cyclopentane (Figure 1.17). This approach also allows for in-
corporation of anomeric pure EANs into an oligonucleotide strand.84 
 
Figure 1.17: Fapy!dG with a cyclopentane- instead of a sugar-moiety. 
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1.4 Synthesis of Oligonucleotides 
The first chemical synthesis of a dinucleotide with a 3’ % 5’ internucleotidic linkage, 
which was identical to natural DNA, was reported in 1955 by Michelson and Todd.85 In their 
pioneering approach, they activated the 5’-protected thymidine-3’-O-benzyl hydrogen phos-
phonate by N-chlorosuccnimide (NCS) and added a 3’-protected thymidine. After removal of 
the protecting groups, the natural thymidylic acid was obtained. 
The first oligonucleotide synthesis that used a solid support was investigated by 
Letsinger and Mahadevan in the mid-sixties.86 The major advantage of this concept, that was 
already known from peptide synthesis, is the facile separation of the starting material and re-
agents in the soluble phase from the product, which is covalently bound to the solid support. 
Thus, no time-consuming purification steps were needed. Nowadays, the most commonly 
used approach is the phosphoramidite approach, developed by Beaucage and Caruthers.87 
The reaction cycle of the phosphoramidite methodology is shown in Figure 1.18. 
 
Figure 1.18: Synthetic cycle of the phosphoramidite methodology. 
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The phosphoramidite methodology follows a 5’ % 3’ chain elongation direction. The 
cycle contains three steps: the coupling step, a capping/oxidation step and the detritylation. In 
the end, the strand is cleaved from the solid support. 
In the coupling step, the phosphoramidite is typically activated with 1H-tetrazole, then 
reacted with a 5’-deprotected nucleoside bound to the solid support (Scheme 1.5). 
 
Scheme 1.5: Phosporamidite activation and coupling step. 
 
The next step includes capping and oxidation. There are always some nucleosides, that 
will not succeeded in coupling in the previous step and therefore still contain a free 5’-OH 
group. These uncoupled hydroxy groups are treated with a mixture of 1-methylimidazole in 
THF and 2,6-dimethylpyrimidine in Ac2O in order to deactivate them for further reactions in 
the following steps. After capping, the phosphite is oxidised by treatment with I2 and water in 
THF/pyridine to the phosphate (Scheme 1.6). 
 
Scheme 1.6: Oxidation of the phosphite. 
 
In the last step of the cycle, the DMT protecting group at the 5’-position is cleaved 
under acidic conditions, usually by treatment with trichloroacidic acid (TCA) in CH2Cl2. 
Then, the 5’-end of the strand is ready for the next coupling step (Scheme 1.7). 
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Scheme 1.7: Deprotection step. 
 
After the last cycle, the oligonucleotide is treated with aq. NH3-solution at elevated 
temperature in order to fully deprotect the oligonucleotide strand and remove it from the solid 
support. Under basic conditions, all protecting groups on the nucleobases and on the phos-
phates are cleaved and the linker to the solid support is released (Scheme 1.8). 
 
Scheme 1.8: Cleavage of protecting groups and solid support. 
 
1.5 ITC 
To determine the binding strength and stability of a duplex, the most commonly used 
technique is the recording of melting curves by UV or circular dichroism (CD). Thereby, a 
single binding constant Kd is determined, from which $G° can be calculated by Equation 1.1. 
To determine the thermodynamic parameters $H° and $S°, a van’t Hoff analysis is necessary. 
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In a van’t Hoff analysis, Ka values at different temperatures are measured. Then, a plot of 1/T 
versus lnKa gives the $H° and $S° values.  
 
$G° = -RTln(Ka)        (1.1) 
$G° = $H° - T$S°        (1.2) 
 
However, isothermal titration calorimetry (ITC) gives Ka and $H° directly in one an-
alysis. By using Equations 1.1 and 1.2, $G° and $S° can easily be calculated. Upon associa-
tion of a host (H) and a guest (G), heat will either be released or absorbed. In ITC, the heat 
released or absorbed in each titration step is measured by comparison of the temperature 
changes that occur between a sample cell where guest is added to host, and a reference cell 
with the same medium as in the sample cell but lacking the guest and host (shown in Figure 
1.19).88 
 
Figure 1.19: Diagram of an isothermal titration calorimeter.
89
 
 
Equation 1.3 shows the total heat (Q) released or absorbed for all the additions of 
guest, where V is the volume of the vessel. Now, the binding isotherm for [H•G] is needed 
(Equation 1.4). A binding isotherm is the theoretical change in the concentration of one com-
ponent as a function of the concentration of another component at constant temperature. 
Equation 1.4 is derived from Equation 1.5, using the relationship that [H]0 = [H•G] + [H], 
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where [H]o is the initial concentration of H and [H•G] is the concentration of host-guest com-
plex.90 
Q = V$H° [H•G]         (1.3) 
 
 
(1.4) 
 
 
(1.5) 
 
Using the binding isotherm (Equation 1.4) for [H•G] gives Equation 1.6. 
       
 
 
(1.6) 
 
Now, why can the heat released or absorbed directly be related to the enthalpy? The 
first law of thermodynamics state that the internal energy of a closed system is constant, thus: 
  dU = dq + dw        (1.7) 
with U being the internal energy, q the heat and w the work. The enthalpie H is given in 
Equation 1.8. 
  H = U + p!V        (1.8) 
Generally, from a change of state follows U % U + dU, p % p + dp and V % V + dV, thus, 
from Equation 1.8, a change in enthalpy can be written as: 
 H + dH = U + dU + (p + dp)(V + dV) 
  = U + dU + p!V + p!dV + dp!V + dp!dV 
U + p!V can be substituted with H (from Equation 1.8) and dp!dV is negligible because it is 
the product of two infinitesimal variables. With Equation 1.7, it follows: 
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 dH = dq + dw + p!dV + dp!V      (1.9) 
In a mechanical equilibrium with the environment, dw = -p!dV can be substituted in Equation 
1.9, giving: 
 dH = dq + dp!V        (1.10) 
At constant pressure (p = 0), it follows: 
 dH = dq        (1.11) 
And for measurable changes: 
 $H = qp       (1.12) 
An isobaric calorimeter like ITC measures q, and so we obtain directly $H, the change in en-
thalpy. 
Despite the fact that ITC can directly deliver a complete thermodynamic characterisa-
tion from one single titration, there are not many examples for measurements of DNA duplex 
formation by ITC.91,92 To determine the binding strength of DNA towards another DNA 
strand, melting curves or differential scanning calorimetry (DSC) are most commonly used. 
The reason might be that the first ITC instruments needed relatively big amounts of material – 
a requirement that limits the usability for DNA. However, the sensitivity of these instruments 
has improved dramatically over the past 15-20 years.89 Thus, sample requirements are now 
accessible for biological systems like DNA. One example, where the complexation between 
oligonucleotides was investigated by ITC, is a study by Bruylants et al. The authors compared 
the pairing stability of a locked nucleic acid (LNA)-DNA heteroduplex and of its isosequen-
tial DNA-DNA homoduplex.91 They did not measure single nucleoside differences, though. 
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2 Problem Outline 
 
2.1 The Project 
Of the present day nucleobases, cytosine is the least stable and is known to undergo 
hydrolysis to uracil. Based on this fact, cytosine can be seen as a hydrolysis product of 2,4-
diaminopyrimidine (Figure 2.1). 
 
Figure 2.1: Hydrolysis of 2,4-diaminopyrimidine (D) to cytosine (C) and uracil (U). 
 
With these three pyrimidine bases as building blocks, an all-pyrimidine base pairing 
code can be formed, as proposed by Siegel and Tor.39 It consists of the two natural nucleo-
sides cytidine and uridine as well as the two unknown nucleosides D and E, both forming 
their glycosidic bond through an exocyclic amino group. D, containing a 2,4-
diamionpyrimidine nucleobase, is isosteric to adenosine (A) and can form base pairs with U. 
E is based on a cytosine nucleobase but in contrast to C, its base is connected via the exocyc-
lic amino function in the 4-position to the ribose moiety. E is isosteric to guanosine (G) and 
forms base pairs with C (Figure 2.2). 
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Figure 2.2: All-pyrimidine base pairing code. 
 
Following our hypothesis, EAN’s D and E are harbingers of A and G, respectively. 
EAN’s are known to be degradation products of purines in nature under oxidative stress93 (see 
section 1.3). Assuming an oxidative atmosphere on the early earth, purines could not have 
existed without a repair system but EAN’s could. Therefore, EAN’s are plausible precursors 
of purine nucleosides. 
A possible precusour of present-day DNA/RNA should fulfil certain criteria.39 It should 
be compatible with the present system but less fit for environmental pressure to allow for mu-
tational evolution. It should be isosteric with the modern system but thermodynamically less 
stable. Additionally, it should fulfil the single source criterion, meaning that a single hetero-
cycle should have established a protocode. 2,4-diaminopyrimidine meets all these criteria. In 
addition, it was synthesised under presumably prebiotic conditions from guanidine hydro-
chloride and cyanoacetaldehyde, as shown by Miller and coworkers94, and from cyanat and 
cyanoacethylene by Shapiro95. 
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2.2 State of Knowledge 
Despite the successful synthesis of pyrimidine based EAN’s by Greenberg et al.81, 
earlier attempts in our group to synthesise exocylic amino nucleoside dD failed. Greenberg’s 
synthesis seems to be limited to electron-poor aromatic rings. Furthermore, EAN’s can easily 
undergo anomerisation, furanose-pyranose isomerisation and cleavage of the glycosidic 
bond.77,80 For these synthetic as well as stability reasons, we switched to carbon analogues, 
since studies by Greenberg and co-workers could show them to be suitable model com-
pounds.77,99 Additionally, Berstis could show computationally that 2,4-diaminopyrimidine (D-
NH2) and 2-aminopyrimidine (D) afford a similar electron distribution like their natural ana-
logue adenine (Figure 2.3). 96 
 
Figure 2.3: Calculated electron distributions for adenine, 2-aminopyrimidine (D) and 2,4-
diaminopyrimidine (D-NH2). 
 
A strategy for the synthesis of homo-C-nucleoside dD was developed in our group and 
is shown in Scheme 2.1.97,98 The synthesis starts from commercially available 2-deoxy-D-
ribose and proceeds in three steps to compound 5. By treatment of 5 with Zn(OAc)2 under 
basic conditions, the "/# ratio can be shifted to a two-fold excess of the desired #-anomer. 
Unfortunately, the anomers cannot be separated by column chromatography. The synthesis is 
continued with the addition of the Bredereck’s reagent, followed by condensation of guani-
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dinium sulfate. This leads to aminopyrimidine 7 as main product but also to side product 8, 
which results from the addition of the Bredereck’s reagent at the position C(1) instead of the 
C(3) of 5. By tuning the reaction conditions, the amount of side product could be reduced but 
not completely avoided. Furthermore, of the main product as well as the side product, an "- 
and #-anomer are obtained. This leads to four different products, which are not separable by 
column chromatography but need to be separated by HPLC. Finally, dD (9) can be obtained 
by deprotection of the isolated #-anomer of 7 with BBr3. 
 
Scheme 2.1: Synthesis of dD. 
 
In the same work, several attempts to synthesise homo-C-nucleoside dE were under-
taken (Scheme 2.2.).97 
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Scheme 2.2: Attempted synthesis of dE. 
 
The first attempts focused on synthesising dE from dD. Simple hydrolysis of dD to 10 
under basic conditions was not successful. Therefore, the conversion of dD to its 2-
iodopyrimidine 11 was tested but after screening various reaction conditions, no yield higher 
than 19 % could be obtained. 
Because of these low yields, alternative strategies were tested. Scheme 2.3 shows two 
different strategies. The first one pursued a Wittig reaction but the Wittig reagent could not be 
synthesised. Treatment of different 4-methylpyrimidine compounds with NBS always resul-
ted in 5-bromo-4-methylpyrimidine instead of the desired bromination of the methyl group. 
The other strategy shown in Scheme 2.3 sought a coupling of the lactone of deoxyribose to a 
double lithiated 4-methylpyrimidone. This strategy was not successful due to a ring opening 
during the nucleophilic attack. 
Despite all these different synthesis attempts it was not possible to obtain dE. 
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Scheme 2.3: Alternative strategies. 
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3 Results and Discussion 
 
3.1 Retrosynthetic Analysis 
The existing synthesis of dD is described in Section 2.2. This synthesis works but suf-
fers from several drawbacks. The main disadvantage is the need for an HPLC separation, 
which is very time-consuming and costly and does not allow the synthesis of bigger quantities 
of material. Additionally, the yield of the key step, the addition of the Bredereck’s reagent 
followed by guanidinium condensation, at 22 %, is rather low. Furthermore, it was not pos-
sible to obtain dE via this synthetic route. For all these reasons, we decided to investigate dif-
ferent synthesis ways that are more time efficient and allow the production of bigger amounts 
of material.  
Conceptually, the retrosynthetic disconnection can be made between the C(1’) of the 
ribose and the exocyclic methylene bridge (Figure 3.1, disconnection a) or between the bridg-
ing CH2 and the C(4) of the pyrimidine ring (Figure 3.1, disconnection b).  
 
Figure 3.1: Possible disconnection of dD. 
 
The first synthetic approach towards dD and dE uses a disconnection next to the C(1’) 
of the deoxyribose moiety. The sugar ring is coupled with the pyrimidine ring by a Wittig 
reaction (Scheme 3.1). The R-group on the pyrimidine ring can then be modified to an amino 
group and oxygen in order to obtain dD and dE, respectively. This approach will be explained 
in more detail in Section 3.2.2. 
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Scheme 3.1: Retrosynthetic Wittig approach for the synthesis of dD and dE. 
 
Further retrosynthetic analysis revealed the route shown in Scheme 3.2. In this synthetic 
pathway, the disconnection is made next to the pyrimidine ring. This has the advantage that 
the configuration of the compound is already fixed before the coupling of the two building 
blocks. At this stage, the "- and #-anomer can still be separated by column chromatography. 
When using diastereopure starting material, this would offer a possibility to obviate the time-
intense and costly HPLC separation. A detailed description of the radical-type pathway can be 
found in Section 3.2.2. 
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Scheme 3.2: Retrosynthetic radical-type pathway for the synthesis of dD and dE. 
 
3.2 Synthesis 
In literature, a variety of C-nucleosides have been reported but only few of them con-
tain a methylene bridge connecting the sugar moiety with the pyrimidine ring (so called 
homo-C-nucleosides; for definition of these terms, see Section 1.3.1).99,100 
Here, two different synthetic routes to dD and dE are described. First, a pathway using 
a Wittig reaction to couple the sugar ring to the pyrimidine nucleobase is discussed in Section 
3.2.1. Second, an attempt including a radical reaction in the coupling step is presented in Sec-
tion 3.2.2. 
 
3.2.1 Wittig Approach 
A Wittig reaction, discovered by Georg Wittig in 1954, is the reaction of an aldehyde or 
ketone and a phosphonium ylide, usually a triphosphonium ylide, to form an alkene.101 
Triphosphonium ylide is also called Wittig reagent. Its synthesis proceeds through a bromina-
tion, followed by conversion to the triphenylphosphonium salt and reduction to the ylide. 
Earlier attempts in our group to synthesise the Wittig reagent of the pyrimidine bases (shown 
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in Scheme 3.3) failed, since bromination by NBS always occurred in the 5-position directly on 
the ring instead of the desired bromination of the exocyclic methyl group on the C(4).97 
 
Scheme 3.3: Bromination by NBS in the 5-position of the pyrimidine ring. 
 
On the other hand, Strekowski et al. were able to brominate 4-methyl-2-
(methylthio)pyrimidine on the methyl group by using Br2 in acetic acid.
102 Following these 
results, we treated 2-hydroxy-4-methylpyrimidine hydrochloride with Br2 in acetic acid but 
obtained bromination in the 5-position (Scheme 3.4). Steinauer observed the same 5-position 
bromination using benzoyl protected 2-amino-4-methylpyrimidine.103 
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Scheme 3.4: Bromination by Br2. 
 
On account of these results we decided to use the thiomethylpyrimidine to form the 
Wittig reagent and, in a later step, to modify the thiogroup to the desired amino or keto group. 
This procedure has the additional advantage that only one precursor is needed to obtain both, 
dD and dE. In Scheme 3.5, the synthesis of the Wittig reagent is shown. It starts from com-
mercially available 4-methylpyrimidine-2-thiol hydrochloride. Methylation by iodomethane 
afforded 4-methyl-2-(methylthio)pyrimidine 15 in good yield.104 The following bromination 
step yielded the desired product 16 brominated on the exocyclic methyl group as main pro-
duct in 54 % yield.102 Two different dibromo sideproducts, 17 and 18, were observed in small 
quantities (5 % and 3 %, respectively). Also a considerable amount of starting material could 
be recovered. The product, as well as the two side products, were obtained as lightly coloured 
oils that decompose overnight at room temperature to black sticky solids. The product should 
therefore be used immediately in the next reaction step or stored at -20 °C for not longer than 
a day. Bromopyrimidine 16 was then treated with triphenylphosphine to give the phos-
phonium salt 19, followed by elimination to the Wittig reagent 20.100 
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Scheme 3.5: Synthesis of the Wittig reagent. 
The synthesis of the second building block, the deoxyribose moiety, is shown in 
Scheme 3.6. 
 
Scheme 3.6: Synthesis of the deoxyribose building block. 
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Commercially available 2-deoxy-D-ribose was oxidised to the lactone 21 by bromine in 
water in quantitative yield.105 Next, the hydroxy groups were protected by TBDMS protecting 
groups. Finally, the compound was reduced by DIBAlH to obtain lactole 23 in very good 
yield, according to a literature procedure.106 
With these two building blocks in hand, a Wittig reaction could be performed to link 
the sugar moiety to the pyrimidine nucleobase (Scheme 3.7). Lactole 23 is in equilibrium with 
its open ring aldose form, which provides the aldehyde needed for the Wittig reaction to pro-
ceed. This aldehyde reacted with the phoshponium ylide to form 24 and triphenylphosphine 
oxide. Intermediate 24 was then treated with NaOMe in MeOH to obtain 25 in an anomeric 
mixture. Traces of 24 could be separated by column chromatography and again subjected to 
NaOMe in MeOH to repeat the ring closing step and obtain more product 25. 
 
Scheme 3.7: Wittig reaction. 
 
The "- and #-anomer of 25 could not be separated by column chromatography, thus, 
HPLC was used for the separation. First, several attempts were made in reverse phase with 
various water-acetonitrile gradients on a C5, a phenyl and different C18 columns. All of these 
attempts showed only one peak and no separation. Then, it was switched to a normal phase 
system where we obtained slight separation on an amino column and finally satisfying separa-
tion on an nitrile column with a isocratic hexane + 0.1 % isopropanol eluent (Figure 3.2). 
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Using this eluent, we were able to separate a sufficient amount of the anomeric mixture to 
obtain the pure anomers. 
 
Figure 3.2: HPLC separation of "- and #-anomer of 25 with hexane + 0.1 % iPrOH as elu-
ent. 
 
2D-NMR measurements (COSY, NOESY) were performed on both anomers separately 
in order to find out which is the desired #-anomer. With help of these measurements it was 
possible to assign the bigger peak in the HPLC absorbance spectrum to belong to the #-
anomer and the second, smaller peak to the "-anomer. Thus, the Wittig reaction resulted in a 
25" /25#-ratio of 1:2. 
Pure compound 25#  was then used as a precursor for the synthesis dD, as described be-
low. 
 
3.2.1.1 Synthesis of dD and its CE PA 
The synthesis towards dD and its cyanoethyl phosphoramidite (CE PA) was continued 
as shown in Scheme 3.8. 
3. Results and Discussion 
 
 
 61 
 
Scheme 3.8: Synthesis of dD CE PA (31). 
 
The first step was the oxidation of the thiol 25#  to sulfone 26#  by treatment with 
mCPBA.107 In the next step, sulfone 26 was reacted with aq. NH3 in dioxane at 80 °C to give 
amine 27, according to a literature procedure.108 Despite the fact, that only the #-anomer was 
used as educt in this reaction, an anomeric mixture of "/# 1:5 was obtained of amine 27. 
Anomerisation seemed to occur during the reaction in the presence of base at elevated tem-
peratures. Using the same reaction conditions but increasing the temperature to only 40 °C did 
not show any improvement. The reaction did not proceed completely and anomerisation could 
still be observed. These results were unsatisfying since only the pure #-anomer is of interest 
for this project and the result of the labour intense HPLC purification step was destroyed dur-
ing this amination step. The synthesis was continued with the "/# mixture to test the feasi-
bility of the synthesis and also to see if addition or substitution of protecting groups have an 
influence on the separation behaviour of the anomers by column chromatography. For exam-
ple, Delaney and Greenberg99 could separate the "- from the #-anomer of their homo-C-
nucleoside when protected with a trityl group on the 5’-hydroxy group. 
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In the next step, the amino function was protected with a benzoyl protecting group. Fol-
lowing a literature procedure109, selective monobenzoylation was achieved by treatment with 
aq. ammonia after the addition of benzoyl chloride. It followed deprotection with NH4F as 
fluoride source to yield diol 29.110 The final steps, following well-known literature proced-
ures, include protection of the 5’ hydroxy group by the bulky dimethoxytrityl protecting 
group111 (which selectively adds to the primary 5’-hydroxy group but not the secondary 3’-
hydroxy group due to steric hindrance) followed by a conversion of the 3’-hydroxy group to a 
cyanoethyl-N,N-diisopropyl phosphoramidite 31.109 This final dD cyanoethyl phosphora-
midite (dD CE PA) is the form needed to be used on an automated DNA synthesiser in order 
to incorporate dD into an oligonucleotide strand. 
 
3.2.1.2 Synthesis of dE 
To convert the thiomethyl function into the oxopyrimidine, several possible procedures 
were investigated. As a starting point, a test reaction was performed, following an old litera-
ture procedure.112 In this test reaction, 4-methyl-2-(methylthio)pyrimidine 15 was treated with 
32 % HCl solution at 130 °C. The reaction afforded 4-methyl-2-hydroxypyrimidine as its hy-
drochloride in good yield (Scheme 3.9). 
 
Scheme 3.9: Test reaction for the functionalisation of the 2-(thiomethyl)pyrimidine to the 
oxopyrimidine. 
 
The same reaction conditions were then transferred to compound 25. Since TBDMS 
protecting groups are known to be labile to strong acids113 we expected to obtain deprotected 
product 33 (Scheme 3.10, entry 1). However, the conditions seemed to be too harsh since full 
decomposition took place (Scheme 3.10, entry 2). Using diluted HCl (Scheme 3.10, entry 3) or 
reducing the temperature to 60 °C (Scheme 3.10, entry 4), resulted in a deprotection of com-
pound 25. However, the thiomethyl group did not react. We decided to convert thiomethyl 25 
to sulfone 26 first and then try the same reaction conditions again because sulfones are the 
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better leaving groups. But this time, only decomposition could be observed (Scheme 3.10, 
entry 5). Additionally, the reaction was tried in the presence of aq. base instead of acid but 
with no success (Scheme 3.10, entry 6). Finally, thiomethyl 25 was treated with aq. base 
where upon partial decomposition could be observed and some starting material could be re-
covered (Scheme 3.10, entry 7).  
 
Scheme 3.10: Reaction attempts towards dE (33) with different reaction conditions. 
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Since all these attempts failed to form dE, we tried a slightly different route with one 
more step included (Scheme 3.11, top). First, sulfone 26 was treated with NaOMe in MeOH to 
give 35.114 The next step should deprotect the methoxy funcion in presence of lewis acidic 
BBr3 to give the desired ketone
115 but treatment with BBr3 only led to deprotection of the 
TBDMS groups and did not react with the methoxy group. Also, a special procedure to depro-
tect methoxy groups on aromatic rings in presence of TMS-I failed in our hands116. The pro-
duct’s mass could be observed by ESI-MS when analysing the reaction mixture, however, the 
product could never be isolated. 
Because methyl groups are generally difficult to cleave when used as protecting groups 
for alcohols,117 it was switched to a benzyl protecting group. The synthesis procedure was 
analogical to the synthesis of methoxy nucleoside 35 but with NaOBn instead of NaOMe as 
nucleophile. The obtained nucleoside 37 was then treated with BBr3 according to a literature 
procedure115. The treatment with Lewis acid did not only cleave the benzyl protecting group 
but also the TBDMS groups, so that the free diol was obtained (Scheme 3.11). Since the de-
protection would be the next step anyway, this saves one step. The rather low yield of 24 % 
describes the yield at the first try, so there is a high potential for optimisation of the reaction.  
 
Scheme 3.11: Unsuccessful (top) and successful (bottom) synthesis of dE (36). 
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3.2.2 Radical Pathway 
As described in Section 3.1, a fundamental different pathway to the Wittig route was 
designed as well. In this radical pathway, named after its last synthetic step that includes a 
radical reaction, the methylene bridge belongs to the sugar moiety and can therefore be fixed 
in its #-form prior to the coupling to the pyrimidine base. This would circumvent the neces-
sity of time-consuming anomer separation by HPLC. 
 
Scheme 3.12: Synthesis of the xanthate nucleoside building block. 
 
Scheme 3.12 shows the synthesis of the xanthate building block, needed for the radical 
reaction in the final coupling step. It starts from 2-deoxy-D-ribose, which has been converted 
to acetal 2 almost quantitatively. Protection of the free hydroxy groups with p-toluoyl protect-
ing groups gave 38 as an anomeric mixture.118 For the formation of Hoffer’s chlorosuger 39, a 
literature procedure by Rolland et al. was followed.119 This procedure is based on the original 
procedure by Hoffer120 but instead of inserting HCl gas it proceeds through in situ generation 
of HCl which is easier to handle and promises higher yields. The following nucleophilic sub-
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stitution to 40 in presence of TMSCN was done according to a procedure by Grünefeld and 
Richert.121 In principle, the reaction could also be performed with NaCN instead of TMSCN 
but the authors claimed to obtain higher yields with the latter. Nucleoside 40 was obtained in 
an anomeric mixture of "/# 1:5 and was separable by column chromatography. The synthesis 
was continued with the pure #-anomer. Conversion to compound 42 was achieved in two 
steps through an acid intermediate, which was not purified but directly reduced to alcohol 
42.122 In the following step, 42 was converted to bromide 43 in very good yield. Treatment 
with potassium ethylxanthate afforded the xanthate sugar building block needed to perform 
the final radical coupling.123  
The other building block for the radical reaction, the pyrimidine ring, is commercially 
available. 2-hydroxypyrimidine hydrochloride and benzoyl protected 2-anminopyrimidine can 
theoretically be used in order to synthesise dE and dD, respectively. 
With the two building blocks in hand, the coupling reaction could be investigated. We 
followed a procedure by Osornio et al.124, using dilauroyl peroxide (DLP) as radical initiator 
to perform an oxidative radical alkylation (Scheme 3.13). DLP was added slowly by syringe 
pump over a 12 h period of time. Unfortunately, no coupled product 46 was detected, only 
starting material could be recovered. 
 
Scheme 3.13: Unsuccessful radical coupling reaction. 
 
In order to proceed, the reaction needs to form a primary radical intermediate, which is 
known to be very unstable (Scheme 3.14). The result of the reaction leads to the conclusion 
that the primary radical did not form at all and the coupling reaction could therefore not take 
place. In fact, the xanthates used in literature to perform radical couplings are always secon-
dary xanthates or placed next to a carbonyl function that helps stabilising the radical.125 Since 
such a stabilised radical would not lead to the desired product for this project, this synthetic 
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strategy was not investigated any further. Nevertheless, bromocompound 43 might be a useful 
reaction partner in another kind of coupling reaction. 
 
Scheme 3.14: Proposed mechanism showing the formation of the unstable primary radical. 
 
3.2.3 Synthesis of an abasic site nucleoside 
An abasic site (As) is a nucleoside that lacks the heterocycle involved in Watson-Crick 
base pair formation.126 The cyanoethyl phosphoramidite of a 2-deoxy abasic site was synthe-
sised in order to be incorporated into oligonucleotide strands. It was then used as a reference 
compound for the binding strength of the nucleoside analogue dD. 
Like the syntheses described above, the synthesis of the abasic site starts from 2-deoxy-
D-ribose (Scheme 3.15). The two first steps to compound 38 are identical with the starting 
steps of the radical pathway (see Section 3.2.2). Acetal 38 was then converted by triethylsi-
lane in the presence of boron trifluoride to 47, following a literature procedure.127 It followed 
the de-esterification to diol 48127 and subsequent protection of the 5’-hydroxy group with 
DMT111. Finally, the compound was converted to its cyanoethyl phosphoramidite form (dAs 
CE PA, 50).109 
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Scheme 3.15: Synthesis of dAs CE PA (50).  
 
3.3 Crystallisation attempts 
One of the major drawbacks of the original synthesis strategy (see Section 2.1) as well 
as the Wittig pathway (see Section 3.2.1) is the fact that the anomeric mixture does not resolve 
with standard silica column chromatography. The anomers could be isolated but necessitated 
separation by HPLC, which does not allow for a scale up of the synthesis and even for small 
scales, it is time-consuming and costly. Another difficulty of the work with the homo-C-
nucleosides in this project is the fact that they have in most cases the appearance of an oil. 
The reason for this oily consistence is probably the methylene bridge, which induces an addi-
tional degree of freedom to the molecule and makes it more flexible and therefore less acces-
sible to crystallisation. Oils are generally more difficult to handle, when it comes to drying of 
the compound, for instance. 
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It would be very instrumental to find a way to crystallise one or both anomers. First of 
all, a crystal structure would allow to gain insight into the three dimensional structure of the 
molecules. Then, with one of the anomers being more likely to precipitate from a solution, 
separation would be facilitated. Even if such a fractional crystallisation is not possible, the 
crystalline form might change the elution properties of the anomers on a silica column in a 
way that separation will become possible. Finally, solids are easier to handle than oils. 
For all these reasons, different strategies were investigated with the overall goal of ob-
taining crystals of homo-C-nucleoside dD or its derivatives. The general approach was to add 
different protecting groups to the molecule, some of them known to have good crystallisation 
properties, to test for the consistency and to make the molecule bigger in order to facilitate the 
separation on a silica column. There are two functional groups on compound dD where pro-
tecting groups can be added, the hydroxy functions on the sugar moiety or the amino group on 
the pyrimidine ring. We started with screening different groups on the pyrimidine ring, either 
protecting groups for the amino function or substitution of the amino group (Figure 3.3).113 
While the first four compounds were synthesised in this work, the Fmoc protected compound 
was described by Steinauer in her master thesis.103 
 
Figure 3.3: Variation on the pyrimidine R-group for crystallisation purposes. 
 
For all the different R-groups, the compound was always an oil and no improvement of 
anomer separation on a silica column could be observed. Even with the spacious Fmoc pro-
tecting group, no change in elution was detected. 
Therefore, it was decided to focus on protecting groups on the hydroxy function of the 
sugar moiety. The bridging silicon ether, shown in Figure 3.4, was described before by 
Steinauer
103 and has also an oily texture. 
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Figure 3.4: Compound with bridging silicon ether protecting groups, linking the 3’- and 5’-
hydroxy function. 
 
Since silicon containing protecting groups are known to have poor crystallisation prop-
erties113, focus was placed on other, non-silicon containing protecting groups with ether or 
ester functions.  
Delaney and Greenberg99 reported on separation of their homo-C-nucleosides after the 
protection step of the primary 5’-hydroxy function by dimethoxytrityl (DMT), a very spacious 
protecting group. We synthesised two 5’-DMT protected compounds (Figure 3.5), one with a 
thiomethyl group on the pyrimidine ring and the other with a benzoyl protected amino func-
tion, but anomer resolution was not obtained for either compound. Also, both were oils and 
we did not succeed in crystallising them. 
 
Figure 3.5: 5’-DMT protected compounds. 
 
Finally, we screened four different protecting groups, shown in Figure 3.6. The first 
two, 4-bromobenzoyl 52 and 4-nitrobenzoyl 53, are known to facilitate crystallisation. 2-
Naphtoyl 54 was chosen due to its increased ,-surface and 3,5-dimethylbenzoyl 55 is a bulky 
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protecting group without many conformational degrees of freedom. They were all synthesised 
from thiomethyl diol 51 in one protecting step by treatment with the corresponding acid 
chloride in pyridine on the basis of literature procedures.127,128 
 
Figure 3.6: Screening of different protecting groups for crystallisation purposes: 4-
bromobenzoyl, 4-nitropenzoyl, 2-naphtoyl and 3,5-dimethylbenzoyl. 
 
The nitrobenzoyl protected compound 53 was obtained as an oil and did not show any 
anomer separation on column. Therefore, it was focused on the three other compounds which 
where obtained in a solid or wax-like consistency. A solubility screening was performed in 
order to find possible crystallisation solvents. Finally, crystallisations were set up from the 
following solvent mixtures: CH2Cl2-hexane, CH2Cl2-MeOH, CH2Cl2-H2O, MeCN-hexane, 
MeCN-H2O, Et2O-hexane, Et2O-MeOH and Et2O-H2O. Unfortunately, despite all these at-
tempts, no crystals have been obtained, so far. 
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3.4 pKa Determination 
The acidity constant (pKa) of dD (9) was determined by a pH-dependent 
1H NMR 
measurement in D2O. The solution with a 2.5 mM concentration of dD in D2O was first ad-
justed to a low pD by the addition of dil. DCl in D2O, then small aliquots of dil. NaOD in 
D2O were added to increase the pD. After the addition of every aliquot, the pD was measured 
and a 1H-NMR spectrum was recorded. The pD of the D2O solution was obtained by adding 
0.40 to the pH meter reading. As expected, protonation led to a downfield shift for H-signals 
close to the protonation site (Scheme 3.16). In Table 3.1, the results of the titration are sum-
marised, focusing on the HC(6) signal next to the protonation site. 
 
Scheme 3.16: dD (9) with marked position HC(6) in its unprotonated (left, high pH) and pro-
tonated (right, low pH) state. 
 
       
pH pD H-6  pH pD H-6 
1.39 1.79 8.294  7.15 7.55 8.213 
1.46 1.86 8.295  7.48 7.88 8.213 
1.60 2.00 8.296  8.45 8.85 8.213 
2.06 2.46 8.296  8.99 9.39 8.212 
2.73 3.13 8.291  9.54 9.94 8.212 
3.46 3.86 8.280  10.03 10.43 8.211 
4.24 4.64 8.255  11.05 11.45 8.213 
4.40 4.80 8.247  11.84 12.24 8.211 
4.93 5.33 8.226  12.45 12.85 8.211 
5.54 5.94 8.212  12.94 13.34 8.209 
6.38 6.78 8.214     
Table 3.1: pH, pD and its corresponding H-6 shift in ppm. 
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The changes in the chemical shifts were evaluated by a Newton-Gauss nonlinear least-
squares curve-fitting procedure. The relationship between the varying pD values and the ob-
served chemical shift is describe by Equation 3.1.129 
 
 
(3.1) 
 
In Equation 3.1, 'dD and 'dDH represent the chemical shift of the compound dD in its 
deprotonated and protonated form, respectively. pKa/D2O corresponds to the negative logarithm 
of the acidity constant in D2O. The pKa/D2O value was then converted to the pKa/H2O value, de-
scribing the situation in H2O, by using Equation 3.2.
130 
 
(3.2) 
 
In Figure 3.7, the variation of the chemical shift for the C(6) proton in dependence on 
the pD is shown.  
 
Figure 3.7: pD dependence of the 
1
H chemical shifts of HC(6) of dD. 
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From the curve fitting, the pKa value obtained is 4.299±0.033 in D2O. Using Equation 
3.2, the pKa in H2O could be determined as 3.792. This acidity constant can now be compared 
to the pKa values of the natural occurring deoxynucleosides, shown in Figure 3.8 (see also 
Table 1.2 for comparison). 
 
Figure 3.8: Natural nucleosides and dD with its pKa values. 
 
The pKa values of the natural deoxynucleosides are taken from the literature.
58 Accord-
ing to their acidity constants, two groups of natural deoxynucloesides can be formed: those 
with higher pKa values around 9, including dG, dU and T, and those with lower pKa values 
around 4, including dA, dC and dD. The nucleoside with a pKa value closest to the pKa of dD 
is dA with a value of 3.5. This finding supports our hypothesis that dD is an analogue of dA. 
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3.5 ITC measurements 
3.5.1 Oligonucleotides 
To test our hypothesis that dD mimics dA, we incorporated it into oligonucleotides in 
order to perform base pairing studies. The non-self-complementary 13-mer oligonucleotide 
system (Figure 3.9) was described before by Breslauer in a different context.131 
 
Figure 3.9: Investigated complementary oligonucleotides with varying middle positions. 
 
The positions X and Y can be modified. At these middle positions, the natural deoxy-
nucleosides dA, dG, dC and dU as well as dD and an abasic site should be incorporated, leav-
ing 12 different strands to be synthesised, six of each kind. The abbreviations for the different 
oligonucleotides are listed in Table 3.2. 
Strand Oligonucleotide Abbreviation 
Strand “C” 5’-CGCAUGUGUACGC-3’ C_U 
 5’-CGCAUGCGUACGC-3’ C_C 
 5’-CGCAUGAGUACGC-3’ C_A 
 5’-CGCAUGGGUACGC-3’ C_G 
 5’-CGCAUGDGUACGC-3’ C_D 
 5’-CGCAUGAsGUACGC-3’ C_As 
Strand “G” 5’-GCGUACUCAUGCG-3’ G_U 
 5’-GCGUACCCAUGCG-3’ G_C 
 5’-GCGUACACAUGCG-3’ G_A 
 5’-GCGUACGCAUGCG-3’ G_G 
 5’-GCGUACDCAUGCG-3’ G_D 
 5’-GCGUACAsCAUGCG-3’ G_As 
Table 3.2: Abbreviations for the synthesised oligonucleotide strands. 
 
Of all different combinations of complementary strands, ITC measurements were per-
formed, leading to 36 different measurements. The results of these measurements give us a 
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complete set of thermodynamic data and enable us to draw conclusions of the base-pairing 
abilities of homo-C-nucleoside dD in comparison to all other bases. 
Oligonucleotide synthesis was achieved on an automated DNA synthesiser using the 
Phosphoramidite approach, explained in Section 1.4. For more details on the synthesis pro-
cedure see Section 5.2.40. 
 
3.5.2 Student’s t-test 
To test the statistical significance of the data, student’s t-tests were performed. Gener-
ally, a t-test is applied for normal populations in cases where samples are small.132 First, a t-
test was made with all the measurements in which one strand contains an abasic site in the 
middle position against all the other measurements. Y1,..., Y9 represent the measurements 
with one strand containing an abasic site in the middle position and X1,..., X38 represent the 
measurements where no abasic site was included. µx and µy are the means of the population 
from which these samples are drawn. The null and alternate hypotheses are: 
 H0: µx - µy - 0  vs. H1: µx - µy > 0 
with the alternate hypothesis saying that the results of the measurements of abasic site con-
taining strands are significantly lower then the results of all the other measurements and the 
null hypothesis saying that the results of abasic site containing measurements are not signifi-
cantly lower. 
Using the averages and standard deviations from Table 3.3, a t-value of 1.856 is ob-
tained. Consulting the t table, a P-value between 0.05 and 0.025 is found. If we follow the 5% 
rule, H0 can be rejected and µy (containing abasic site) is significantly lower than µx. 
  Average Stdev 
All -210 67 
U -247 67 
C -214 85 
A -245 74 
G -214 54 
D -176 48 
As -163 48 
Table 3.3: Summery of all means and standard deviations (in kJ/mol). 
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A second t-test was made with Y1,..., Y12 representing the measurements with one strand con-
taining the artificial nucleotide D in the middle position and X1,..., X38 representing all meas-
urements with natural nucleotides in the middle position. 
The null and alternate hypotheses are 
 H0: µx - µy - 0  vs. H1: µx - µy > 0 
The obtained t-value is 0.682, corresponding to a P-value between 0.25 and 0.40, meaning 
that we cannot reject the null hypothesis. That does not mean that we can assume the H0 to be 
true but we have evidence that the different means of the two populations is due only to ran-
dom variation. 
In summary, we can assume a significant difference between nucleosides with a nu-
cleobase and those without. Furthermore, there seems not to be significant difference between 
the strands incorporating D in the middle position compared to those with another nucleobase 
in the middle position. Hence, we can assume that nucleoside D shows certain binding prop-
erties comparable to those of the natural nucleosides. 
 
3.5.3 Data analysis 
The process of duplex formation can roughly be divided into two parts. First, the DNA 
single strands form a pre-ordered structure by stacking. Second, the actual duplex formation 
takes place by binding of the two pre-stacked single strands. As pointed out by Vesnaver and 
Breslauer, the pre-ordered single strand already posses over 40 % of the total enthalpy.131 The 
contribution from single-stranded structures is included in the enthalpies measured by ITC. 
Most of the base pair combinations were measured once. Nevertheless, some measure-
ments were repeated to check the precision of the measurements. For example, the combina-
tion with A in the middle positions of both complementary strands was measured twice. In the 
first measurement, the C-strand was titrated to the G-strand in the cell of the calorimeter. This 
gave an enthalpy of -243 kJ/mol. In the repeating measurement, the strands were swapped and 
the G-strand was now titrated to the C-strand, yielding an enthalpy of -241 kJ/mol, which is a 
difference of less then 1%. The same was done with the combination containing D in both 
middle positions. In the first measurement, the C-strand was titrated to the G-strand and an 
enthalpy of -155 kJ/mol was obtained. In the second measurement, the G-strand was added to 
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the C-strand, which gave an enthalpy of -156 kJ/mol. Again, this is a difference of less than 
1 %.  
In Table 3.4, the obtained enthalpies in kJ/mol of all ITC measurements are summa-
rised. All measurements can be found in the appendix. 
   G 
    U C A G D As 
U -294 -285 -397 -227 -221 -176 
C -177 -152 -178 -181 -153 -111 
A -274 
 
 
-384 -243 -204 -210 -167 
G -253 -341 -243 -217 -211 -177 
D -201 -188 -216 -167 -155 -114 
C 
As -161 
 
-271 -188 -127  -123 
 
  
Table 3.4: $H values in kJ/mol. 
 
To check the accuracy of the measurements, the data was compared to a very similar 
system measured by Breslauer et al. They worked with the same sequences which were used 
in this project with the only difference, that their sequences contained T instead of dU. For the 
A:U base pair with the A in the C-strand and the U in the G-strand, we measured $G of -47.9 
kJ/mol, $H of -274 kJ/mol and $S of -758 J/mol*K. Breslauer et al. obtained their thermody-
namic profiles not by ITC but by differential scanning calorimetry (DSC) and temperature-
dependent UV absorbance spectroscopy. They observed $G of 83.7 kJ/mol, $H of 490 kJ/mol 
and $S of 1362 J/mol*K.131 These values are in the same range like the values we observed 
and therefore comparable. The differences in the values probably base on the different tech-
niques used to determine the thermodynamic profile. 
The Watson-Crick base pairs are expected to show the highest binding energies, thus 
the most negative enthalpy values. As can be seen in Table 3.4, they are indeed among the 
strongest, except for the G-C Watson-Crick base pair with C in the middle position of the C-
strand opposite G in the middle position of the G-strand. Rather high binding energies were 
also found for the G:U base pair, which forms a Wobble base pair similar in energy to the 
Watson-Crick base pairs (described in Section 1.2.4.3). 
dD seems to show a certain selectivity for dU. Focusing on the G_D strand, one can see 
that dD shows highest binding energies with an enthalpy of -221 kJ/mol for dU in the C-
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strand. The second highest energies are observed when dD is opposite dG and dA with en-
thalpies of -211 and -210 kJ/mol, respectively. On third place is the binding towards dD and 
dC with -155 and -153 kJ/mol, respectively. As expected, binding towards the abasic site ex-
hibits the lowest binding energy. When focusing on the C-strand with dD in the middle posi-
tion, only the binding towards dA with -216 kJ/mol is stronger than towards dU with -201 
kJ/mol. It follows in order of decreasing binding enthalpies: dC, dG, dD and finally dAs. 
Binding of dD towards dG and dA in comparison of the binding pattern of dD with dU is 
shown in Figure 3.10. Binding towards dA can be explained by rotation of the nucloebase 
around the methylene bridge. In summary, a binding affinity of dD for dU can be observed. 
Additionally, dD shows also a certain binding affinity for dA and dG. The same observations 
were also found by Bischof when he analysed the same systems by melting curves.98 He found 
a slight selectivity of dD for dU but also for dA and, in one case, for dG. 
 
Figure 3.10: Possible binding patterns of dD to natural deoxynucleosides. 
 
dD is presumably an analogue of dA, therefore they should exhibit similar base pairing 
behaviour. Table 3.5 summarises the comparison of the enthalpies of dD and dA in kJ/mol. 
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On the left side, the data for dD and dA in the G-strand opposite all different nucleosides in 
the C-strand are shown. The right side table shows dD and dA in the C-strand opposite all 
different nucleosides in the G-strand. The values are in decreasing binding strength order for 
dD. 
  G     C  
  D A $    D A $ 
U -221 -397 176  A -216 -243 27 
G -211 -243 32  U -201 -274 73 
A -210 
 
 
-243 33  C -188 
 
 
-384 196 
D -155 -216 61  G -167 -204 37 
C -153 -178 25  D -155 -210 55 
C 
As -123 
 
-188 65  
G 
As -114 
 
-167 53 
Table 3.5: Comparison of $H values of dD and dA in (kJ/mol). 
 
Compared to the series with dA in the middle position, dD shows generally lower bind-
ing energies. This can be explained by the additional degree of freedom that the methylene 
bridge of homo-C-nucleosides introduces. The extra flexibility can decrease the binding en-
ergy as well as disrupting the base stacking. Nevertheless, the trends observed in binding of 
dA are similar to the ones of dD. The binding strengths of A in the G-strand are in decreasing 
order: dU, dG and dA, dD, dC. Exactly the same order can be observed for G_D. Not so dis-
tinct but similar is the binding order for C_A compared with C_D. Thus, we can conclude that 
a certain similarity between the binding behaviour of dD and dA can be observed. 
The difference in enthalpy between dD and dA is smaller when they are in the middle 
position of the G-strand. When they are in the C-strand, a larger difference is observed. In 
other words, the binding behaviour of dD is closer to the one of dA when they are in the G-
strand, flanked on both sides of a cytosine. This effect was already observed by melting curve 
analysis of the same oligonucleotides and could be explained by the fact, that cytosine is 
known to induce strong dipoles to its nearest neighbours which fixes the flexibility of the 
homo-C nucleoside dD98. This stacked conformation is then similar to the one of the non-
flexible dA. 
The entropies and Gibbs energies of the systems cannot be measured directly by ITC. 
Nevertheless, they can be calculated by Equations 1.1 and 1.2 as described in Chapter 1.5. 
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The $S values and $G values are summarised in Table 3.6 and Table 3.7, respectively. $S 
values are shown in J/mol*K while $G values are in kJ/mol. 
   G 
    U C A G D As 
U -838 -811 -1165 -620 -607 -452 
C -455 -367 -454 -452 -380 -232 
A -758 
 
 
-1139 -667 -540 -570 -422 
G -704 -978 -657 -586 -578 -465 
D -539 -498 -590 -424 -392 -248 
C 
As -404 
 
-773 -494 -286 -284 
 
  
Table 3.6: $S values in J/mol*K. 
 
   G 
    U C A G D As 
U -44.1 -43.2 -49.7 -42.3 -40.0 -41.1 
C -41.4 -42.6 -42.5 -46.3 -39.8 -41.7 
A -47.9 
 
 
-44.3 -44.1 -42.9 -40.1 -41.1 
G -43.2 -49.4 -47.1 -42.2 -38.8 -38.5 
D -40.2 -39.5 -40.0 -40.6 -38.2 -39.9 
C 
As -40.5 
 
-40.5 -40.6 -41.6 -38.3 
 
  
Table 3.7: $G values in kJ/mol. 
The obtained free energies are in the range of -38.2 to -49.7 kJ/mol. These values are 
small compared to the measured enthalpies of -111 to -397 kJ/mol and the entropic term (-
T$S) of 69.1 to 347 kJ/mol. While the duplex formation is highly favoured by enthalpy, it is 
nearly as much unfavoured by entropy. These two opposing contributions are much larger 
than the resulting free energy which stabilises the duplex only slightly. This effect is known 
in literature for other oligonucloetides133,134. 
Like in the case of the enthalpies, Watson-Crick base pairs are among the most favour-
able in terms of free energy. The five most negative $G values come from the four Watson-
Crick base pairs as well as the G:A combination in the middle position. The later might result 
from the three neighbouring deoxyguanosines in the middle position of the C-strand, that ex-
hibit high stacking energies. 
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Even if the $G values are lower and the resulting trends therefore less pronounced then 
for the $H values, the conclusions for dD are similar like those drawn from the enthalpies. It 
must be noted that all of the $G values are in the same range and rather close together. For 
the series with dD in the middle position of the G-strand, the most favourable free energies 
are those of the measurement opposing A with -40.1 kJ/mol and the measurement opposing U 
with -40.0 kJ/mol. Then, it follows in decreasing order C, G, As and D. The order for dD in 
the C-strand is slightly different. The most favourable free energy occurs for G in the opposite 
position, with a $G value of 40.6 kJ/mol, followed by U with 40.2 kJ/mol. Then, in decreas-
ing order, it follows A, As, C and D. Like in the comparison of the enthalpies, we can observe 
a slight selectivity of dD towards, dU, dA and dG in terms of free energy. 
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4 Outlook 
 
As shown in the previous chapter, dD exhibits a certain ability to mimic dA. This find-
ing opens many new possibilities. A particularly interesting field would be PCR-like experi-
ments. Two different sets of experiments are possible. In one set, a template strand with dD 
incorporated would be mixed with a primer, a polymerase and the natural triphosphates ATP, 
GTP, CTP and UTP. Following the hypothesis that dD mimics dA, the polymerase would 
incorporate dU opposite dD. In the other set of experiments, DTP could be mixed with differ-
ent template strands, a primer and a polymerase to observe from the opposite of which nu-
cleoside would the polymerase incorporate dD. According to the hypothesis, it should be in-
corporated opposite dU, but not opposite of the other nucleosides. 
In this work, we managed to synthesis homo-C-nucleoside dE for the first time (see 
Section 3.2.1.2). With this synthetic strategy, it is now possible to synthesise the phosphora-
midite form of dE, to incorporate it into oligonucleotide strands and, as done in this work with 
dD, to determine its thermodynamics by ITC. It would allow for evaluation of an all-
pyrimidine system. 
A crucial point of the presented hypothesis is the synthesis of dD as well as dE under 
prebiotic conditions, which was not part this project. Nevertheless, it should be investigated in 
order to establish the EANs dD and dE as precursor of present-day nucleosides.  
In principle, every biochemical process that uses adenosine could be a possible target 
for exchange of dA with dD. Examples are ATP, CoA, NAD+ or NADP+. Additionally, it 
might be worthwhile to test for antibiotic or antiviral activities of dD, since many EANs like 
Clitocine and also some C-nucleosides show such activities and are used as active ingredient 
in drugs (see Section 1.3.1). 
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5 Experimental Part 
 
5.1 General 
Reagents and Solvents: All reagents were used as purchased from commercial suppli-
ers unless otherwise stated. For reactions, solvents of pro analysis grade were used. For reac-
tions performed under dry atmosphere, solvents of puriss. grade were used. For work up and 
purification, distilled solvents of technical grade were used. 
Chromatography: Thin layer chromatography (TLC): Merck TLC aluminium sheets, 
silica gel 60 F254, 2 mm. Column chromatography (CC): Sigma-Aldrich Silica gel Merck Type 
9385, 230-400 mesh, 60 Å. 
High-performance liquid chromatography (HPLC): Normal phase: Analytical 
HPLC: Shimadzu LC-10AT, Spherisorb®-NH2, 5 #m, 25 cm x 4.6 mm. Reverse-phase (RP): 
YMC basic, 5 #m, 15 cm x 10 mm. Preparative HPLC: Shimadzu LC-8A, Spherisorb®-NH2, 5 
#m, 25 cm x 20 mm. 
Melting Points (M.p.): Heating microscope from Christoffel Labor- und Betriebstech-
nik; Melting points are uncorrected. 
Infrared Spectroscopy (IR): Jasco 4100 FT-IR spectrometer; absorption values in 
cm–1 and intensity (s: strong, 0-30 % transmission; m: middle, 30-60 % transmission; w: 
weak, 60-100 % transmission). 
Nuclear Magnetic Resonance (NMR): 1H-, 13C and 31P-NMR: Bruker AV-300, AV-
400 or AV-500 instruments. 13C-signal multiplicity was deduced from DEPT 90 and DEPT 
135 spectra (Disortionless Enhancement by Polarization). Peak assignment was performed by 
two-dimensional NMR experiment (NOESY, COSY). 
Mass Spectrometry (MS): Finnigan Trace GC ultra instrument equipped with a 
Zebron ZB-5MS capillary GC column for CI and EI; Finnigan Surveyor MSQ quadrupole 
spectrometer for ESI; m/z (rel. %); Bruker Autoflex I spectrometer for MALDI-TOF (matrix-
assisted laser desorption/ionisation time of flight). 
pKa Titration: Acidity constants were determined by pH-dependent 
1H NMR meas-
urement on a Bruker AV-500 insturment in D2O. The change of the chemical shift of HC(6) 
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was evaluated in dependence on adjustement of the pD values by DCl and NaOD. The ex-
periment was performed at 2.5 mM concentration in 0.7 ml D2O (298 K, I = 0.1 M NaNO3). 
The centre peak of tetramethylammonium ion (0.5 mM; ' = 3.1776 ppm rel. to TMS) was 
used as internal reference. The pH was measured with a Hamilton Minitrode glass electrode 
connected to a Metrohm 605 digital pH meter. 0.4 log units were added to the pH-meter read-
ing to obtain the corresponding pD of the D2O solution. The change in chemical shift of the 
HC(6) proton in dependence on the pD was evaluated by a Newton-Gauss non-linear least-
squares curve-fitting procedure. 
Isothermal Titration Calorimetry (ITC): All batches were dialyzed previous to any 
use against a large volume of milli-Q H2O with a MW cutoff of 1 kDa. The oligonucleotide 
concentrations were determined spectrophotometrically by measuring the absorbance. A 
pH = 7 10 mM sodium phosphate buffer with 1.0 M NaCl and 1 mM EDTA, was used. ITC 
experiments were performed at 25 °C on a VP-ITC MicroCalorimeter from MicroCal. All 
samples were degassed under vacuum prior to the titration experiments. Aliquots of 10 µl of a 
solution of one of the strands of a known precise concentration (in the 50 µM range) were 
injected into the 1.4 ml titration cell containing the solution of the complementary strand (in 
the 5 µM range). 25 injections were typically performed for each set of experimental condi-
tions at intervals of 240 s to ensure the return to equilibrium. Blank experiments were per-
formed in order to take ligand dilution heat into consideration (heat removed before analysing 
the titration data). The dilution heats were identical to the heat signals detected after satura-
tion was reached. Data analysis were performed using a nonlinear least-squares fitting algor-
ithm software (MicroCal Origin 7.1) with a 1:1 binding. The heat of the first injection was 
systematically removed for analysis. 
UV Spectra: Agilent 8453UV-Vis spectrophotometer. 
 
5.2 Synthesis 
 
5.2.1 Methyl-2-deoxy-!/"-D-ribofuranosid (2) 
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2-Deoxy-D-ribose 1 (13.65 g, 101.77 mmol) was solved in 250 ml MeOH. 28 ml of 1% HCl 
in MeOH was added. After stirring for 50 min at rt, silver carbonate (4.98 g, 18.10 mmol) was 
added and it was filtered through celite. The solvent was evaporated under reduced pressure 
and it was dried at the HV overnight at 40 °C. A yellow oil (14.47 g, 99 %) was obtained. 
 
1
H-NMR (300 MHz, CDCl3): ! 5.14 (d, J = 2.1 Hz, 1 H, HC(1), "-2), 5.11 (d, J = 4.0 Hz, 1 
H, HC(1), !-2), 4.16-4.11 (m, 1 H, HC(3), "/#-2), 4.08-4.04 (m, 1 H, HC(4), "/#-2), 3.74-
3.58 (m, 2 H, H2C(5), "/#-2), 3.39 (s, 3 H, H3CO, "/#-2), 2.18-1.89 (m, 2 H, H2C(2), "/#-2). 
13
C-NMR (75 MHz, CDCl3): ! 105.3, 105.2 (C(1), "/#-2), 87.0, 86.7 (C(4), "/#-2), 72.3, 
71.7 (C(3), "/#-2), 64.7, 63.4 (C(5), "/#-2), 55.2, 54.8 (OCH3, "/#-2), 41.9, 41.2 (C(2), "/#-
2). 
 
5.2.2 Methyl-3,5-di-O-benzyl-2-deoxy-!/"-D-ribofuranosid (3) 
 
To a solution of 2 (14.47 g, 97.66 mmol) in 200 ml dry THF under Ar, NaH (8.78 g, 365.83 
mmol) was added under ice cooling, followed by the addition of IN(Bu)4 (0.33 g, 0.91 mmol) 
and benzylbromide (22 ml, 31.68 g, 185.21 mmol) and it was stirred overnight at rt. 
It was filtered and Et2O was added. The ether phase was washed with sat. NaHCO3 solution, 
sat. NaCl solution and water. It was dried over Na2SO4, the solvents were evaporated and it 
was purified by column chromatography (SiO2, Hex/Et2O 3:1) to give 3 (19.02 g, 58 %) as a 
yellow oil. 
 
Rf (SiO2, Hex/Et2O 3:1): 0.24, 0.35 ("- and #-anomer) 
IR (film): 3648w, 2081m, 3060s, 3026s, 3001m, 2922s, 2851s, 2336w, 1943w, 1871w, 
1804w, 1747w, 1667w, 1601m, 1583w, 1540w, 1493s, 1452s, 1365m, 1328w, 1313w, 1207w, 
1180m, 1154m, 1096s, 1049s, 1028s, 966m, 907m, 841w, 754s, 702s, 619w, 540m. 
5. Experimental Part 
 
 
 87 
1
H-NMR (300 MHz, CDCl3): ! 7.33-7.23 (m, 10 H, arom. H, "/#-3), 5.06 (ddd, J = 7.0, 5.3, 
1.7 Hz, 1 H, HC(1), "/#-3), 4.55-4.44 (m, 4 H, benz. H, "/#-3), 4.24 (tt, J = 7.1, 3.6 Hz, 1 H, 
HC(4), "/#-3), 4.12 (ddd, J = 6.7, 5.9, 3.8 Hz, 1 H, HC(3’), "-3), 3.95 (ddd, J = 7.9, 4.4, 2.8 
Hz, 1 H, HC(3’), #-3), 3.50 (dt, J = 7.3, 3.4 Hz, 2 H, H2C(5’), "/#-3), 3.38 (s, 3 H, H3CO, "-
3), 3.28 (s, 3 H, H3CO, #-3), 2.23-1.97 (m, 2 H, H2C(2’), "/#-3). 
13
C-NMR (75 MHz, CDCl3): ! 138.2, 138.2, 138.1, 138.0 (arom. Cipso, "/#-3), 128.4, 128.4, 
127.9, 127.7, 127.7, 127.6 (arom. C, "/#-3), 105.5 (C(1), #-3), , 105.2 (C(1), "-3), 82.9 (C(4), 
#-3), 82.2 (C(4), "-3), 80.0 (C(3), #-3), 78.6 (C(3), "-3), 73.3 (C(5), #-3), 72.0 (C(5), "-3), 
71.6 (benz. CH2, #-3), 70.2 (benz. CH2, "-3), 55.2 (CH3O, #-3), 55.0 (CH3O, "-3), 39.4 
(C(2), #-3), 38.9 (C(2), "-3). 
ESI-MS: 351.1 (100, [M+Na]+). 
 
5.2.3 1-(3', 5'-di-O-benzyl-2'-deoxy-!/"-D-ribofurano-1-yl)-propan-2-one (5) 
 
3 (5.42 g, 16.50 mmol) in 200 ml dry MeCN were cooled to 0 °C under Ar and silylenolether 
4 (3.88 g, 29.78 mmol) was added. Then, SnCl4 (2.7 ml, 5.99 g, 22.99 mmol) was added 
dropwise. It was stirred 2 h at 0 °C. The solvents were evaporated and the residue was dis-
solved in CH2Cl2, washed twice with water and once with sat. NaHCO3 solution. It was dried 
over Na2SO4 and purified by Column Chromatography (SiO2, Hex/Et2O 1:1). 5 (3.45 g, 59 %) 
was obtained as a yellow oil in a "/# 3:1 ratio. Treatment of the product with Zn(OAc)2 
(16.64 g, 90.73 mmol) and NaOMe (4.90 g, 90.73 mmol) in 150 ml MeOH for 3 d at rt shifted 
the anomeric ratio to "/# 1:2. 
 
Rf (SiO2, Hex/Et2O 1:1): 0.15 
IR (film): 3062w, 3030m, 2891w, 2863w, 1712s, 1604w, 1496w, 1454m, 1359m, 1273w, 
1205w, 1163w, 1093s, 1028m, 912w, 737s, 698s, 603w. 
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1
H-NMR (300 MHz, CDCl3): ! 7.31-7.21 (m, 10 H, arom. H), 4.49-4.44 (m, 5 H, benz. H, 
HC(1’), "/#-5), 4.15 (q, J = 4.4 Hz, 1 H, HC(4’), "-5), 4.07 (dt, J = 4.9, 2.6 Hz, 1 H, HC(4’), 
#-5), 4.03 (dd, J = 3.4, 0.6 Hz, 1 H, HC(3’), "-5), 3.98 (dt, J = 6.2, 1.8 Hz, HC(3’), #-5), 
3.49-3.36 (m, 2 H, H2C(5’), "/#-5), 2.90 (dd, J = 16.5, 6.8 Hz, 1 H, HC(1), "-5), 2.74 (dd, J = 
16.0, 6.9 Hz, 1 H, HC(1), #-5), 2.65 (dd, J = 16.4, 6.5 Hz, 1 H, HC(1), "-5), 2.54 (dd, J = 
16.0, 5.8 Hz, 1 H, HC(1), #-5), 2.33 (dt, J = 13.1, 6.7, 1 H, HC(2’), "-5), 2.18 (dd, J = 5.2, 1.5 
Hz, 1 H, HC(2’), #-5), 2.12 (s, H3CO, #-5), 2.11 (s, H3CO, "-5), 1.71 (ddd, J = 13.1, 5.6, 4.2, 
1 H, HC(2’), "-5), 1.57 (ddd, J = 13.2, 10.2, 6.3 Hz, 1 H, HC(2’), #-5). 
13
C NMR (75 MHz, CDCl3): ! 208.8 (CO, "-5), 208.3 (CO, #-5), 139.5, 139.4 (arom. Cipso, 
"/#-5), 129.7, 129.0, 128.9 (arom C, "/#-5), 84.8 (C(4’), #-5), 83.8 (C(4’), "-5) 82.3 (C(3’), 
#-5), 82.2 (C(3’), "-5), 76.2 (C(1’), "-5), 76.0 (C(1’), #-5), 74.7 (C(5’), "/#-5), 72.8, 72.4, 
72.2, 72.1 (benz. CH2, "/#-5), 51.2 (C(1), "-5), 50.6 (C(1), #-5), 39.5 (C(2’), #-5), 39.1 
(C(2’), "-5), 31.9 (C(3), "-5), 32.0 (C(3), #-5). 
ESI-MS: 377.26 (100, [M+Na]+). 
 
5.2.4 2-Amino-4-((3',5'-di-O-benzyl-2'-deoxy-"-D-ribofurano-1-yl)methyl)pyrimidine 
(7 ") 
 
To 5 (0.20 g, 0.57 mmol) in 2 ml dry toluene, BuOCH(NMe2)2
135 (0.15 g, 0.86 mmol) was 
added under Ar. It was stirred for 20 h at 70 °C. After evaporation of the solvent, the residue 
was solved in 4 ml abs. EtOH under Ar.  NaOEt (0.07 g, 1.08 mmol) was added and it was 
stirred for 4 h at 60 °C. After cooling down to 40 °C, guanidinium sulfate (0.47 g, 2.16 mmol) 
was added and it was stirred for 1.5 h at 40 °C. Then, it was stirred for 18 h at 70 °C. The sol-
vents were evaporated. Purification by CC (SiO2, Hex/EtOAc 1:8) gave a mixture of 7 and 8 
(0.07 g, 22 %) as an anomeric mixture. 
HPLC separation (Hex/MeOH/EtOH 97:2:1) provided 7" as a yellow oil. 
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Rf (SiO2, EtOAc/Hex 8:1): 0.25 
IR (film): 3333s, 3182m, 3089m, 3071m, 3033m, 2937w, 2867s, 1959w, 1892w, 1817w, 
1636s, 1585s, 1496m, 1464s, 1368m, 1349m, 1276m, 12010m, 1099s, 1062s, 1034w, 916w, 
813w, 748s, 712s, 618w.  
1
H-NMR (300 MHz, CDCl3): ! 8.16 (d, J = 5.0 Hz, HC(6)), 7.38–7.20 (m, arom. H), 6.57 (d, 
J = 5.1 Hz, HC(5)), 5.10 (s br, H2N), 4.56 (s, H2COC(5’)), 4.57–4.45 (m, HC(1’)), 4.48 (s, 
H2COC(3’)), 4.17 (dt, J = 5.2, 2.6 Hz, HC(4’)), 4.05 (dt, J = 6.6, 2.0, HC(3’)); 3.54 (dd, J = 
10.0, 3 J = 4.7 Hz, HC(5’)), 3.44 (dd, J = 10.1, 3 J = 5.2 Hz, HC(5’)), 2.90 (dd, J = 13.9, 6.9 
Hz, HCC(4)), 2.77 (dd, J = 13.9, 5.7 Hz, HCC(4)), 2.12 (ddd, J = 13.2, 5.2, 1.5 Hz, H!C(2’)), 
1.72 (ddd, J = 13.2, 10.2, 6.4 Hz, H"C(2’)). 
13
C NMR (75 MHz, CDCl3): ! 168.4 (C(4)), 162.7 (C(2)), 157.9 (C(6)), 138.0, 137.9 (arom. 
Cipso), 128.4, 128.43, 128.1, 127.7, 127.6, 127.5 (arom. C), 111.4 (C(5)), 83.5 (C(4’)), 81.0 
(C(3’)), 77.2 (C(1’)), 73.2 (COC(5’)), 70.8 (COC(3’)), 70.6 (C(5’)), 43.2 (CC(4)), 38.0 
(C(2’)). 
ESI-MS: 854.2 (100, [M+Na]+). 
 
5.2.5 4-methyl-2-(methylthio)-pyrimidine (15) 
 
2-Mercapto-4-methylpyrimidine hydrochloride 14 (4.98 g, 30.63 mmol) was suspended in 60 
ml EtOH and 60 ml 1 M aq. NaOH was added, followed by the addition of MeI (1.9 ml, 4.31 
g, 30.39 mmol). It was stirred for 4 h at rt, then partially evaporated and extracted with EtOAc 
twice. The org. phase was washed with H2O and sat. NaCl solution, dried over Na2SO4, ev-
aporated under reduced pressure and dried at the HV overnight. 15 (3.50 g, 82 %) was ob-
tained as a yellow liquid.  
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IR (film): 2926w, 1567s, 1541s, 1414m, 1372w, 1342m, 1325s, 1266w, 1217s, 1205s, 1182m, 1035w, 
967w, 882m, 820w, 769m, 730w, 710m, 580w, 543m. 
1
H-NMR (300 MHz, CDCl3): ! 8.29 (d, J = 5.1 Hz, 1 H, HC(6)), 6.80 (d, J = 5.1 Hz, 1 H, 
HC(5)), 2.54 (s, 3 H, H3CS), 2.44 (s, 3 H, H3C)). 
13
C NMR (75 MHz, CDCl3): ! 172.2 (C(2)), 167.3 (C(4)), 156.6 (C(6)), 116.0 (C(5)), 24.1 
(CH3), 14.0 (SCH3). 
GC-MS: tR = 5.20 min; 140 (100, M
+), 94 (76, M - SCH3), 67 (74). 
 
5.2.6 4-bromomehtyl-2-methylthiopyrimidine (16) 
 
To 15 (0.5 ml, 0.50 g, 3.60 mmol) in 4.8 ml acetic acid, Br2 (0.19 ml, 0.61 g, 3.81 mmol) was 
added by syringe and it was stirred for 2 h at 80 °C under N2. After letting cool down to rt, 
Et2O was added. The formed precipitation was filtered, treated with aq. NaHCO3 solution and 
extracted with Et2O. The org. phase was washed with sat. NaCl solution, dried over Na2SO4, 
and evaporated under reduced pressure. CC (SiO2, CH2Cl2/hexane 1:1 to 100 % CH2Cl2) af-
forded 16 (0.43 g, 54 %) as a brown oil. 
 
Rf (SiO2, CH2Cl2/hexane 1:1): 0.39 
1
H-NMR (300 MHz, CDCl3): ! 8.52 (d, J = 5.1 Hz, 1 H, HC(6)), 7.11 (d, J = 5.1 Hz, 1 H, 
HC(5)), 4.36 (s, 2 H, H2C), 2.57 (s, 3 H, H3CS). 
13
C-NMR (75 MHz, CDCl3): ! 173.1 (C(2)), 165.3 (C(4)), 158.2 (C(6)), 115.4 (C(5)), 31.8 
(CH2Br), 14.4 (CH3S). 
GC-MS: tR = 7.90 min; 220 (11, M
+), 218(10, M+), 139 (100, M-Br), 93 (26), 66 (44). 
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5.2.7 5-bromo-4-bromomehtyl-2-methylthiopyrimidine (17) 
 
17 was obtained as a side product of the synthesis of 16 and isolated by CC purification 
(0.05 g, 5 %). 
 
Rf (SiO2, CH2Cl2/hexane 1:1): 0.81 
1
H-NMR (300 MHz, CDCl3): ! 8.56 (s, 1 H, HC(6)), 4.48 (s, 2 H, H2C), 2.56 (s, 3H, H3CS). 
GC-MS: tR = 9.62 min; 300 (7, M
+), 298 (13, M+), 296 (7, M+) 219 (87, M – Br), 217 (100, M 
– Br), 96 (45), 64 (74). 
 
5.2.8 4-dibromomehtyl-2-methylthiopyrimidine (18) 
 
18 was obtained as a side product of the synthesis of 16 and isolated by CC purification 
(0.03 g, 3 %). 
 
Rf (SiO2, CH2Cl2/hexane 1:1): 0.51 
1
H-NMR (300 MHz, CDCl3): ! 8.62 (d, J = 5.2 Hz, 1 H, HC(6)), 7.39 (d, J = 5.2 Hz, 1 H, 
HC(5)), 6.40 (s, 1 H, HCBr2), 2.58 (s, 3 H, H3CS). 
GC-MS: tR = 9.36 min; 300 (8, M
+), 298 (14, M+), 296 (8, M+) 219 (89, M – Br), 217 (95, M 
– Br), 137 (89), 92 (63), 64 (100). 
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5.2.9 Triphenylphosphanylidene thiomethyl-pyrimidine (19) 
 
Triphenylphosphine (0.62 g, 2.37 mmol) in 2 ml dry benzene was added to 16 (0.37 g, 1.69 
mmol) in 5 ml dry benzene and it was stirred for 4 h at rt under Ar. It was filtered, washed 
with benzene and dried at the HV overnight to give 19 (0.41 g, 60 %) as a bright pink solid. 
 
M.p.: > 220 °C (decomposition). 
IR (film): 3445w, 3048w, 2834w, 2339w, 1733w, 1556s, 1437s, 1350m, 1200m, 1109s, 996w, 
913w, 868w, 748m, 720s, 688s, 511s, 444w. 
1
H-NMR (300 MHz, DMSO-d6): ! 8.43 (d, J = 5.0 Hz, 1 H, HC(6)), 7.77-7.63 (m, 15 H, 
Ph3P), 7.05 (d, J = 5.0, 1 H, HC(5)), 5.40 (d, J = 15.6 Hz, 2 H, H2C), 1.95 (s, 3 H, H3CS). 
 
5.2.10 Triphenylphosphine thiomethyl-pyrimidine (20) 
 
19 (3.00 g, 7.47 mmol) was solved in a biphasial mixture of 30 ml H2O, 60 ml ice and 117 ml 
CH2Cl2. 13.4 ml 1 M aq. NaOH was added in one portion and it was stirred for 1 h at rt. The 
phases were separated and the water phase was extracted twice with CH2Cl2. The org. phase 
was dried over Na2SO4, evaporated under reduced pressure and dried at the HV overnight to 
give 20 (2.44 g, 82 %) as a beige foam. 
 
1
H-NMR (300 MHz, CDCl3): ! 8.37 (d, J = 5.1 Hz, 1 H, HC(6)), 7.71-7.43 (m, 15 H, Ph3P), 
6.82 (d, J = 5.1, 1 H, HC(5)), 6.19 (d, J = 5.9 Hz, 1 H, HC=PPh3), 2.56 (s, 3 H, H3CS). 
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ESI-MS: 401 (100, [M+H]+). 
 
5.2.11 2-deoxy-D-ribono-1,4-lactone (21) 
 
1 (7.12 g, 53.06 mmol) was dissolved in 230 ml H2O and cooled to 0 °C. Br2 was added 
dropwise and it was stirred for 16 h at 0 °C. It was evaporated under reduced pressure, the 
residue was dissolved in acetone, filtered through celite and washed with acetone. It was ev-
aporated under reduced pressure and dried at the HV to give 21 (7.00 g, 99 %) as a dark vis-
cous oil. 
 
IR (film): 3415w, 1771m, 1190w, 1056w, 505w, 417m. 
1
H-NMR (300 MHz, aceton-d6): ! 4.38 (dt, J = 6.4, 2.2 Hz, 1 H, HC(4)), 4.22 (m, 1 H, 
HC(3)), 3.61 (dd, J = 4.1, 3.7 Hz, 2 H, H2C(5)), 2.73 (dd, J = 17.7, 6.5 Hz, 1 H, HC(2)), 2.18 
(dd, J = 17.7, 1.9 Hz, 1 H, HC(2)). 
13
C NMR (75 MHz, aceton-d6): ! 175.4 (C=O), 88.1 (C(4)), 68.5 (C(3)), 61.5 (C(5)), 37.9 
(C(2)). 
 
5.2.12 3,5-bis-O-(tert-butyldimethylsilyl)-2-deoxy-D-ribono-1,4-lactone (22) 
 
To lactone 21 (7.01 g, 53.06 mmol) and imidazole (15.08 g, 221.46 mmol) in 60 ml dry DMF 
at 0 °C under Ar, TBDMSCl (17.50 g, 116.10 mmol) in 40 ml dry DMF was added dropwise. 
It was stirred for 21 h at rt under Ar. The reaction mixture was poured into 300 ml of EtOAc, 
filtered over celite and washed with EtOAc. The filtrate was partially evaporated, then 
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washed with 0.5 M aq. HCl, H2O and sat. NaCl solution, dried over Na2SO4 and evaporated. 
Filtration through a 5 cm layer of SiO2 (CH2Cl2-hexane 2:1) afforded 22 (12.14 g, 63 %) as a 
beige solid. 
 
Rf (SiO2, CH2Cl2/hexane 2:1): 0.29 
M.p.: 76.0 - 78.2 °C. 
IR (KBr): 2957s, 2857s, 1769s, 1473m, 1390m, 1361m, 1260s, 1172s, 1127m, 1094m, 
1008m, 969m, 944m, 916w, 839s, 781s, 665m, 601w, 540w.  
1
H-NMR (300 MHz, CDCl3): ! 4.50 (dt, J = 6.6, 2.4 Hz, 1 H HC(4)), 4.32 (q, J = 2.6 Hz, 1 
H, HC(3)), 3.78 (dd, J = 3.2, 2.3 Hz, 2 H, H2C(5)), 2.81 (dd, J = 17.7, 6.7 Hz, 1 H, HC(2)), 
2.38 (dd, J = 17.6, 2.6 Hz, 1 H, HC(2)), 0.88 (t, J = 2.1 Hz, 18 H, 2x (H3C)3CSi), 0.08-0.06 
(m, 12 H, 2x (H3C)2Si)). 
13
C-NMR (75 MHz, CDCl3): ! 175.7 (C=O), 88.6 (C(4)), 70.9 (C(3)), 63.5 (C(5)), 39.4 
(C(2)), 26.27, 26.16 ((H3C)3CSi), 18.9, 18.6 ((H3C)3CSi), -4.6, -4.6, -5.3, -5.4 ((CH3)2Si). 
 
5.2.13 3,5-bis-O-(t-butyldimethylsilyl)-2-deoxy-D-ribofuranose (23) 
 
DIBAlH (1.5 M in toluene, 33.5 ml, 50.25 mmol) was added dropwise to 22 (12.14 g, 33.65 
mmol) in 150 ml dry Et2O at -78 °C under Ar and it was stirred for 5 h. 35 ml MeOH were 
added dropwise and it was let warm to 0 °C. Na/K-tartrate (0.5 M, 100 ml) was added and it 
was stirred overnight at rt. Et2O was added, separated and the org. phase was washed with 
0.5 M Na/K-tartrat solution and H2O. It was dried over Na2SO4 and evaporated under reduced 
pressure. CC (SiO2, 100 % CH2Cl2 to CH2Cl2/ Et2O 8:1) afforded 23 (11.61 g, 95 %) as a light 
yellow oil. 
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Rf (SiO2, CH2Cl2/hexane 2:1): 0.15 
IR (film): 3428w, 2954m, 2929m, 2886w, 2858m, 1472w, 1362w, 1254m, 1118m, 1083m, 
1006w, 836s, 776s, 675w. 
1
H-NMR (300 MHz, DMSO-d6): ! 6.17 (d, J = 5.3 Hz, 1 H, "-OH), 6.02 (d, J = 5.3 Hz, 1 H, 
#-OH), 5.33 (q, J = 4.7 Hz, 1 H, HC(1), "-23), 5.22 (td, J = 5.3, 3.7 Hz, 1 H, HC(1), #-23), 
4.24 (ddd, J = 5.7, 4.7, 3.2 Hz, 1 H, HC(3)), 4.05 (dt, J = 7.9, 6.1 Hz, 1 H, HC(4)), 3.63-3.48 
(m, 2 H, H2C(5)), 2.28 (ddd, J = 13.2, 7.8, 5.5 Hz, 1 H, HC(2)), 1.53 (ddd, J = 13.1, 6.1, 3.6 
Hz, 1 H, HC(2)), 0.83, 0.82, 0.81, 0.80 (4 s, 18 H, 2x (H3C)3CSi), 0.00, 0.00, -0.01, -0.02 (4 s, 
12H, 2x (H3C)2Si). 
13
C-NMR (75 MHz, DMSO-d6): ! 97.7, 96.7 (C(4)), 85.8, 83.2 (C(3)), 72.8, 71.4 (C(1)), 
64.3, 62.4 (C(5)), 42.5, 42.3 (C(2)), 25.7, 25.6 ((H3C)3CSi), 18.0, 17.6 ((H3C)3CSi), -4.8, -4.9, 
-5.0, -5.1 ((CH3)2Si). 
ESI-MS: 385.3 (100, [M+Na]+). 
 
5.2.14 2-Thiomethyl-4-((3',5'-di-O-t-butyldimethylsilyl-2'-deoxy-!/"-D-ribofurano-1-
yl)pyrimidine (25) 
 
23 (1.86 g, 5.12 mmol) and 20 (2.44, 6.09 mmol) were refluxed in dry toluene for 36 h under 
N2. It was evaporated and the residue was resolved in 30 ml MeOH. NaOMe (0.06 g, 1.17 
mmol) was added and it was stirred for 2 h. 1 M NH4Cl and EtOAc was added, separated and 
the org. phase was washed with sat. NaCl. solution, dried over Na2SO4 and evaporated under 
reduced pressure. CC (SiO2, Hexane/EtOAc 20:1 to 10:1) afforded 25 (1.79 g, 72 %) as a pale 
yellow oil with a "/# ratio of 1:2. 
!- and "-anomers were separated by normal phase HPLC on a nitrile column (isocratic 0.1% 
iPrOH in hexane, 30 ml/min). 
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25-#:  
Rf (SiO2, hexane/EtOAc 5:1): 0.32 
IR (film): 2953m, 2927m, 2898w, 2856m, 1568m, 1543m, 1463w, 1335w, 1254m, 1201w, 
1201w, 1092m, 1006w, 938w, 835s, 777s. 
1
H-NMR (300 MHz, CDCl3): ! 8.34 (d, J = 5.1 Hz, 1 H, HC(6)), 6.88 (d, J = 5.1 Hz, 1 H, 
HC(5)), 4.48 (td, J = 10.6, 4.6 Hz, 1 H, HC(1’)), 4.24-4.22 (m, 1 H, HC(3’)), 3.74 (ddd, J = 
5.7, 3.8, 2.1 Hz, 1 H, HC(4’)), 3.46 (ddd, J = 53.3, 10.7, 4.9 Hz, 2 H, H2C(5’)), 2.89-2.84 (m, 
2 H, H2CC(4)), 2.50 (s, 3 H, H3CS), 1.87-1.64 (m, 2 H, H2C(2’)), 0.83 (d, J = 7.0 Hz, 18 H, 
2x (H3C)3CSi), 0.02, 0.00, -0.02, -0.03 (4 s, 12 H, 2x (H3C)2Si). 
13
C-NMR (100 MHz, CDCl3): ! 172.6 (C(4)), 168.7 (C(2)), 157.0 (C(6)), 116.9 (C(5)), 88.4 
(C(4’)), 77.4 (C(3’)), 74.4 (C(1’)), 64.3 (C(5’)), 44.2 (CC(4)), 41.5 (C(2’)), 26.48, 26.32 
((CH3)3CSi), 18.9, 18.5 ((CH3)3CSi), 14.6 (CH3S), -4.14, -4.19, -4.77, -4.87 (CH3)2Si). 
ESI-MS: 485.45 (100, [M+H]+), 507.51 (5, [M+Na]+). 
HPLC (hexane/iPrOH 99:1): tR = 9.4 min. 
 
25-": 
Rf (SiO2, hexane/EtOAc 5:1): 0.32 
1
H-NMR (300 MHz, CDCl3): ! 8.32 (d, J = 5.1 Hz, 1 H, HC(6)), 6.85 (d, J = 5.1 Hz, 1 H, 
HC(5)), 4.44 (ddd, J = 7.4, 5.5, 2.0 Hz, 1 H, HC(1’)), 4.29 (dt, J = 6.2, 3.3 Hz, 3 H, HC(3’)), 
3.83 (dt, J = 4.8, 3.7 Hz, 1 H, HC(4’)), 3.55-3.40 (m, 2 H, H2C(5’)), 3.10-2.83 (m, 2 H, 
H2CC(4)), 2.49 (s, 3 H, H3CS)), 2.17 (dt, J = 12.9, 6.6 Hz, 1 H, H2C(2’)), 1.66 (ddd, J = 12.7, 
4.9, 4.3 Hz, 1 H, H2C(2’)), 0.83 (d, J = 7.0 Hz, 18 H, 2x (H3C)3CSi), 0.01- -0.06 (m, 12 H, 2x 
(H3C)2Si). 
13
C-NMR (125 MHz, CDCl3): ! 172.2 (C(4)), 168.7 (C(2)), 156.9 (C(6)), 116.8 (C(5)), 87.04 
(C(4’)), 78.0 (C(3’)), 73.7 (C(1’)), 63.7 (C(5’)), 44.7 (CC(4)), 40.4 (C(2’)), 26.10, 25.99 
((CH3)3CSi), 18.5, 18.1 ((CH3)3CSi), 14.3 (CH3S), -4.53, -4.59, -5.18, -5.24 ((CH3)2Si). 
ESI-MS: 485.45 (100, [M+H]+), 507.50 (7, [M+Na]+). 
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HPLC (hexane/iPrOH 99:1): tR = 10.3 min. 
 
5.2.15 3’,5’-TBDMS-protected sulfonopyrimidine nucleoside (26) 
 
To 25 (0.11 g, 0.23 mmol) in 1.5 ml dry CH2Cl2 under N2, mCPBA (0.14 g, 0.82 mmol) in 
2 ml dry CH2Cl2 was added and stirred for 16 h at rt. The white precipitation that formed 
overnight was filtered off and the filtrate was washed with 10 % Na2S2O3 solution and H2O, 
dried over Na2SO4 and evaporated under reduced pressure. CC (SiO2, Hexane/EtOAc 3:1) 
afforded 26 (0.09 g, 78%) as a colourless oil. 
 
Rf (SiO2, hexane/EtOAc 3:1): 0.14 
IR (film): 2953m, 2929m, 2894m, 2857m, 1579m, 1471w, 1360w, 1322s, 1254s, 1137s, 
1091s, 1034w, 1007w, 961w, 837s, 778s, 667w, 540m, 419m. 
1
H-NMR (300 MHz, CDCl3): ! 8.77 (d, J = 5.1 Hz, 1 H, HC(6)), 7.57 (d, J = 5.1 Hz, 1 H, 
HC(5)), 4.56-4.50 (m, 1 H, HC(1’)), 4.31 (dd, J = 3.7, 1.8 Hz, 1 H, HC(3’)), 3.79 (ddd, J = 
5.4, 3.7, 1.9 Hz, 1 H, HC(4’)), 3.60 (dd, J = 10.8, 3.8 Hz, 2 H, H2C(5’)), 3.35 (s, 3 H, H3CS) 
3.19-2.98 (m, 2 H, HCC(4)), 1.98-1.71 (m, 2 H, H2C(2’)), 0.88 (d, J = 6.8 Hz, 18 H, 
(H3C)3CSi), 0.06 (s, 12 H, (H3C)2Si). 
13
C-NMR (125 MHz, CDCl3): ! 171.0 (C(4)), 165.7 (C(2)), 157.8 (C(6)), 124.2 (C(5)), 88.1 
(C(4’)), 76.6 (C(3’)), 73.7 (C(1’)), 63.7 (C(5’)), 43.7 (CC(4)), 41.2 (CH3SO2), 39.2 (C(2’)), 
26.0, 25.8 ((CH3)3CSi), 18.4, 18.0 ((CH3)3CSi), -4.6, -4.7, -5.3, -5.4 ((CH3)2Si). 
ESI-MS:  517.48 (70, [M+H]+), 539.51 (100, [M+Na]+), 555.51 (75, [M+K]+). 
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5.2.16 3’,5’-TBDMS-protected 2-aminopyrimidine nucleoside  (27) 
 
26 (0.09 g, 0.18 mmol) was solved in 2 ml dioxane in a pressure tube. 25 % aq. NH3 was 
added and it was stirred for 4 h at 80 °C, then evaporated under reduced pressure. CC (SiO2, 
EtOAc) afforded 27" /#  (0.06 g, 77 %, "/# = 1:5) as a colourless oil. 
 
27#: 
Rf (SiO2, EtOAc): 0.69 
1
H-NMR (300 MHz, CDCl3): ! 8.18 (d, J = 5.2 Hz, 1 H, HC(6)), 6.66 (d, J = 5.2 Hz, 1 H, 
HC(5)), 5.34 (s br, 2 H, H2N), 4.54-4.47 (m, 1 H, HC(1’)), 4.30 (dt, J = 5.5, 2.0 Hz, 1 H, 
HC(3’)), 3.80 (ddd, J = 6.0, 3.9, 2.1 Hz, 1 H, HC(4’)), 3.53 (ddd, J = 57.5, 10.7, 5.0 Hz, 2 H, 
H2C(5’)), 2.83-2.80 (m, 2 H, HCC(4)), 1.93-1.69 (m, 2 H, H2C(2’)), 0.89 (d, J = 6.4 Hz, 18 H, 
(H3C)3CSi)), 0.08-0.03 (m, 12 H, (H3C)2Si). 
13
C-NMR (100 MHz, CDCl3): ! 169.4 (C(6)), 161.8 (C(4)), 156.3 (C(2)), 111.4 (C(5)), 88.2 
(C(4’)), 77.5 (C(3’)), 74.0 (C(1’)), 64.0 (C(5’)), 43.5 (CC(4)), 41.3 (C(2’)), 26.1, 26.0 
((CH3)3C(CH3)2Si), 18.6, 18.2 ((CH3)3C(CH3)2Si), -4.5, -4.4 -5.2, -5.1 ((CH3)3C(CH3)2Si). 
ESI-MS:  454.38 (100, [M+H]+). 
 
27": 
Rf (SiO2, EtOAc): 0.69 
1
H-NMR (300 MHz, CDCl3): ! 8.18 (d, J = 5.2 Hz, 1 H, HC(6)), 6.64 (d, J = 5.2 Hz, 1 H, 
HC(5)), 5.43 (s br, 2 H, H2N), 4.39-4.37 (m, 1 H, HC(1’)), 4.30 (dt, J = 5.5, 2.0 Hz, 1 H, 
HC(3’)), 3.91 (ddd, J = 3.3, 3.0, 2.2 Hz, 1 H, HC(4’)), 3.56 (dq, J = 27.3, 4.6 Hz, 2 H, 
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H2C(5’)), 3.11-2.78 (m, 2 H, HCC(4)), 2.29-1.68 (m, 2 H, H2C(2’)), 0.89 (d, J = 6.4 Hz, 18 H, 
(H3C)3CSi)), 0.08-0.03 (m, 12 H, (H3C)2Si). 
13
C-NMR (100 MHz, CDCl3): ! 170.4 (C(6)), 161.8 (C(4)), 156.3 (C(2)), 111.6 (C(5)), 87.2 
(C(4’)), 77.8 (C(3’)), 73.7 (C(1’)), 63.8, (C(5’)), 44.3 (CC(4)), 40.6 (C(2’)), 26.1, 26.0 
((CH3)3C(CH3)2Si), 18.6, 18.2 ((CH3)3C(CH3)2Si), -4.5, -4.6, -5.1, -5.2 ((CH3)3C(CH3)2Si). 
ESI-MS:  454.38 (100, [M+H]+). 
 
5.2.17 3’,5’-TBDMS-protected benzamine-pyrimidine nucleoside (28) 
  
 
BzCl (0.03 g, 0.22 mmol) was added dropwise to 27 (0.02, 0.05 mmol) in 1 ml dry pyridine at 
0 °C under Ar, then it was stirred for 2 h at rt. It was cooled to 0 °C, then 0.08 ml H2O were 
added and it was stirred for 15 min at 0 °C. 0.27 ml 25 % aq. NH3 solution were added and it 
was stirred for another 30 min at 0 °C. It was evaporated and the residue was dissolved in 
Et2O. It was washed twice with water and the water phases were extracted once with Et2O. 
The org. phase was dried over Na2SO4 and evaporated under reduced pressure. Purification by 
CC (SiO2, hexane/EtOAc 1:1) gave 28 (0.17 g, 61 %) as a colourless oil. 
 
Rf (SiO2, hexane/EtOAc): 0.48 
IR (film): 3246w, 3060w, 2927m, 2856m, 1753m, 1716m, 1593m, 1563m, 1532m, 1450m, 
1389w, 1253m, 1184m, 1087m, 835s, 776s, 737s, 670w. 
1
H-NMR (300 MHz, CDCl3): ! 9.59 (s br, 1 H, HN), 8.62 (d, J = 5.1 Hz, 1 H, HC(6)), 8.14-
8.02 (m, 2 H, arom. Hmeta), 7.64-7.45 (m, 3 H, arom. Hortho, para), 7.13 (d, J = 5.1 Hz, 1 H, 
HC(5)), 4.56 (ddt, J = 9.9, 7.5, 5.0 Hz, 1 H, "/#-HC(1’), 4.41-4.37 (m, 4.41-4.37, 1 H, "-
HC(3’)), 4.38-4.30 (m, 1 H, #-HC(3’)), 3.98-3.94 (m, 1 H, "-HC(4’)) 3.82 (ddd, J = 5.9, 3.9, 
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2.0 Hz, 1 H, #-HC(4’)), 3.66-3.42 (m, 2 H, "/#-H2C(5’)), 3.06-2.93 (m, 2 H, "/#-HCC(4)), 
1.98-1.73 (m, 2 H, "/#-H2C(2’)), 0.92-0.87 (m, 18 H, (H3C)3CSi)), 0.09-0.03 (m, 12 H, 
(H3C)2Si). 
13
C-NMR (100 MHz, CDCl3): ! 169.7 (C(6), !/"-28), 165.0 (C=O, !/"-28), 158.3 (C(4), !/"-
28), 157.7 (C(2), !/"-28), 134.7, 132.5, 129.0, 127.7 (arom Bz-CH, !/"-28), 117.2 (C(5), !/"-
61), 88.2 (C(4’), "-28), 87.1 (C(4’), !-28), 77.9 (C(3’), "-28), 77.4 (C(3’), !-28), 74.0 (C(1’), 
"-28), 73.7 (C(1’), !-28), 64.0 (C(5’), "-28), 63.8 (C(5’), !-28), 44.7 (CC(4), !-28), 43.9 
(CC(4), "-28), 41.3 (C(2’), "-28), 40.5 (C(2’), !-28), 26.2, 26.1, 26.0 ((CH3)3C(CH3)2Si, !/"-
28), 18.6, 18.5, 18.2, 18.2 ((CH3)3C(CH3)2Si, !/"-28), -4.4, -4.5, -4.6, -5.1, -5.2, -5.2 
((CH3)3C(CH3)2Si, !/"-28). 
ESI-MS:  558.63 (100, [M+H]+). 
 
5.2.18 N-(4-((2'-deoxy-"-D-ribofurano-1-yl)-methyl)pyrimidin-2-yl)benzamide (29) 
 
28 (0.02 g, 0.03 mmol) and NH4F in 1 ml MeOH were refluxed for 15 h, then the solvent was 
evaporated. EtOAc and H2O were added, separated and the water phase was extracted with 
EtOAc. The water phase was evaporated under reduced pressure and the residue purified by 
CC (SiO2, EtOAc/MeOH 10:1) to give 29 (0.01 g, 70 %). 
 
Rf (SiO2, EtOAc/MeOH 10:1): 0.11 
1
H-NMR (500 MHz, MeOD): ! 8.56 (d, J = 5.1 Hz, 1 H, HC(6)), 8.01-7.98 (m, 2 H, arom. 
Hmeta), 7.62-7.42 (m, 3 H, arom. Hortho, para), 7.21 (d, J = 5.2 Hz, 1 H, HC(5)), 4.62-4.56 (m, 1 
H, HC(1’)), 4.23 (dt, J = 5.9, 2.4 Hz, 1 H, HC(3’)), 3.79 (td, J = 4.8, 2.7 Hz, 1 H, HC(4’)), 
3.53 (dd, J = 4.8, 1.6 Hz, 2 H, H2C(5’)), 3.03-3.02 (m, 2 H, HCC(4)), 2.02-1.85 (m, 2 H, 
H2C(2’)). 
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13
C-NMR (125 MHz, MeOD): ! 170.4 (C(6)), 167.6 (C=O), 158.3 (C(4)), 158.1 (C(2)), 
132.7, 129.8, 128.9, 128.28 (arom. C (Bz)), 117.7 (C(5)), 88.2 C(4’)), 77.6 (C(3’)), 73.1 
(C(1’)), 63.1 (C(5’)), 43.3 (CC(4)), 40.8 (C(2’)). 
ESI-MS:  330.16 (100, [M+H]+), 352.16 (70, [M+Na]+). 
 
5.2.19 N-(4-((5'-O-(4'',4'''-dimethoxytrytil)-2'-deoxy-"-D-ribofurano-1-yl)-
methyl)pyrimidin-2-yl)benzamide (30) 
 
29 (0.01 g, 0.02 mmol), DMTCl (0.01 g, 0.04 mmol), DMAP (0.001 g, 0.008 mmol) and 
NEt(iPr)2 (0.01 ml, 0.008 g, 0.06 mmol) in 0.5 ml dry pyridine were stirred for 24 h at rt 
under Ar. It was evaporated and the residue was dissolved in CH2Cl2 containing 1 % TEA, 
washed twice with H2O, dried over Na2SO4 and evaporated under reduced pressure. CC 
(SiO2, EtOAc/TEA 200:1) afforded 30 (0.005 g, 36 %) as a yellow oil.  
 
Rf (SiO2, EtOAc/TEA 200:1): 0.47 
1
H-NMR (500 MHz, CDCl3): ! 8.56 (d, J = 5.1 Hz, 1 H. HC(6)), 7.90-7.88 (m, 2 H, benz. H), 
7.58-7.17 (m, 12 H, 3 arom. H (Bz) and 9 arom. H (Tr)), 7.02 (d, J = 5.1 Hz, 1 H, HC(5)), 
6.82-6.80 (m, 4 H, arom. H (Tr)), 4.62 (dd, J = 9.4, 6.3 Hz, 1 H, HC(1’)), 4.34-4.33 (m, 1 H, 
HC(3’)), 3.93 (ddd, J = 5.4, 4.4, 3.0 Hz, 1 H, HC(4’)), 3.78 (s, 3 H, H3CO), 3.15 (ddd, J = 
59.9, 9.7, 5.1 Hz, 2 H, H2C(5’)), 3.03-2.98 (m, 2 H, HCC(4)), 2.07-1.92 (m, 2 H, H2C(2’)). 
13
C-NMR (125 MHz, CDCl3): ! 169.2 (C(4)), 164.8(C=O), 158.5 (Cpara (PhOMe)), 157.5 
(C(6)), 157.3 (C(2)), 144.9 (Cipso (Ph)), 136.1 (Cipso (PhOMe)), 134.4 (Cipso (Bz)), 132.2 (Cpara 
(Bz)) 130.1 (Cortho (PhOMe)), 128.8, 128.2, 127.9, 127.5 (Cortho (Ph), Cmeta (Ph), Cortho (Bz), 
Cmeta (Bz)), 126.8 (Cpara (Ph)), 117.0 (C(5)), 113.1 (Cmeta (PhOMe)), 86.0 (C(4’), 84.6 (Ctert 
(Tr)), 77.3 (C(3’)), 74.2 (C(1’)), 64.4 (C(5’)), 55.3 (CH3O), 43.7 (CC(4)), 40.6 (C(2’)). 
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5.2.20 (1-((N
2'
-Benzoyl(2-aminopyrimidin-4-yl))methyl)-5-O-(4,4-dimethoxytrityl)-2-
deoxy-"-D-ribofurano-1-yl)-"-cyanoethyl-N,N-diisopropyl phosphoramidite (31) 
 
To 30 (0.005 g, 0.007 mmol) in 0.05 ml dry CH2Cl2 under Ar, NEt(
iPr)2 (0.005 ml, 0.004 g, 
0.03 mmol) was added by syringe, followed by PClN(iPr)2OEtCN (0.01 g, 0.04 mmol) in 0.05 
ml dry CH2Cl2. It was stirred for 3 h at rt, then 0.2 ml MeOH was added, followed by EtOAc 
containing 0.5 % of TEA. The org. phase was washed with H2O, sat. NaHCO3 solution and 
sat. NaCl solution, dried over Na2SO4 and evaporated under reduced pressure. Purification by 
CC (SiO2, CH2Cl2/EtOAc/TEA 100:100:1) gave 31 (0.006 g, 91 %) as a pale yellow foam. 
 
Rf (SiO2, CH2Cl2/EtOAc/TEA 100:100:1): 0.82 
1
H-NMR (500 MHz, CDCl3): ! 8.58 (dd, J = 5.1, 1.6 Hz, 1 H, HC(6)), 7.90 (dd, J = 6.7, 1.3 
Hz, 2 H, HCortho (Bz)), 7.56-7.52 (m, 1 H, HCpara (Bz)), 7.49-7.43 (m, 2 H, Hmeta (Bz)), 7.35-
7.16 (m, 9 H, arom. H (Tr)), 7.06 (d, J = 4.4 Hz, 1 H, HC(5)), 6.83-6.78 (m, 2 H, HCmeta 
(PhOMe)), 4.61-4.56 (m, 1 H, HC(1’)), 4.46-4.42 (m, 1 H, HC(3’)), 4.21 (td, J = 9.8, 6.0 Hz, 
1 H, HC(4’)), 3.77, 3.75 (2 s, 6 H, H3CO), 3.66-3.64 (m, 2 H, H2C(5’)), 3.57 (q, J = 7.3 Hz, 2 
H, OCH2CH2CN), 3.31-3.03 (m, 2 H, NCHMe2), 2.93 (q, J = 7.3 Hz, 2 H, H2CC(4)), 2.61-
2.55 (m, 2 H, OCH2CH2CN), 2.10-1.85 (m, 2 H, H2C(2’)), 1.27-1.21 (m, 12 H, 
((CH3)2CH)2N). 
13
C-NMR (125 MHz, CDCl3): ! 169.1 (C(4)), 164.6 (C=O), 158.4 (Cpara (PhOMe)), 157.5 
(C(6)), 157.2 (C(2)), 144.9 (Cipso (Ph)), 136.0 (Cipso (PhOMe)), 134.6 (Cipso (Bz)), 132.0 (Cpara 
(Bz)), 130.1 (Cortho (PhOMe)), 128.7, 128.2, 127.8, 127.3 (Cortho (Ph), Cmeta (Ph), Cortho (Bz), 
Cmeta (Bz)),126.7 (Cpara (Ph)), 117.6 (CN), 116.8 (C(5)), 113.1 (Cmeta, (PhOMe), 86.0 (Ctert 
(Tr)), 84.9 (C(4’)), 76.9 (C(1’)), 75.0 (C(3’)), 64.1 (C(5’)), 58.1 (OCH2CH2CN), 55.2 
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(CH3O), 43.8 (CC(4)), 43.1 (NCHMe2), 38.9 (C(2’)), 24.7 ((CH3)2CH)2N), 20.0 
(OCH2CH2CN). 
31
P-NMR (203 MHz, CDCl3): ! 147.9, 147.8. 
ESI-MS:  832.61 (18, [M+H]+), 303.19 (100, DMT). 
 
5.2.21 3’,5’-TBDMS-protected methoxypyrimidine nucleoside (35) 
 
Sulfone 26 (0.07 g, 0.14 mmol) and NaOMe (0.05 g, 0.89 mmol) in 5 ml MeOH were re-
fluxed for 3 h under N2. After cooling down to rt, CH2Cl2 was added and the org. phase was 
washed twice with H2O, dried over Na2SO4 and evaporated under reduced pressure. It was 
purified by CC (SiO2, hexane/EtOAc 2:1) which gave 35 (0.05 g, 78 %) as a colourless oil. 
 
Rf (SiO2, hexane/EtOAc 2:1): 0.80 
1
H-NMR (300 MHz, CDCl3): ! 8.39 (d, J = 4.9 Hz, 1 H, HC(6), 35-"/#), 6.94-6.89 (m, 1 H, 
HC(5), 35-"/#), 4.56-4.53 (m, 1 H, HC(1’), 35-"/#), 4.45-4.35 (m, 1 H, HC(3’), 35-"), 4.30-
4.28 (m, 1 H, HC(3’), 35-#), 4.01 (s, 3 H, H3CO, 35-"/#), 3.91-3.90 (m, 1 H, HC(4’), 35-"), 
3.80-3.78 (m, 1 H, HC(4’), 35-#), 3.63-3.40 (m, 2 H, H2C(5’), 35-"/#), 3.20-2.95 (m, 2 H, 
H2CC(4), 35-"), 2.92 (d, J = 6.3 Hz, 2 H, H2CC(4), 35-#), 2.30-1.71 (m, 2 H, H2C(2’), 35-
"/#), 0.88 (d, J = 7.7 Hz, 18 H, (H3C)3CSi, 35-"/#), 0.07-0.02 (m, 12 H, (H3C)2Si, 35-"/#). 
13
C-NMR (125 MHz, CDCl3): ! 172.6 (C(4), 35-#), 172.3 (C(4), 35-"), 168.7 (C(2), 35-#), 
168.6 (C(2), 35-"), 157.1 (C(6), 35-#), 156.9 (C(6), 35-"), 116.9 (C(5), 35-#), 116.7 (C(5), 
35-"), 88.6 (C(4’), 35-#), 88.1 (C(4’), 35-"), 77.6 (C(3’), 35-"), 77.3 (C(3’), 35-#), 73.9 
(C(1’), 35-"), 73.7 (C(1’), 35-#), 64.2 (C(5’), 35-"), 64.0 (C(5’), 35-#), 54.9 (OCH3, 35-"), 
54.4 (OCH3, 35-#),  44.7 (CC(4), 35-"), 44.1 (CC(4), 35-#), 41.4 (C(2’), 35-#), 40.7 (C(2’), 
35-"), 26.5, 26.2 (((CH3)3CSi), 35-#), 26.0, 25.9 ((CH3)3CSi), 35-"), 19.1, 18.6 ((CH3)3CSi), 
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35-#), 18.6, 18.0 ((CH3)3CSi), -4.1, -4.1, -4.7, -4.8 (CH3)2Si, 35-#), -4.5, -4.6, -5.1, -5.2 
((CH3)2Si, 35-#). 
ESI-MS:  469.45 (100, [M+H]+). 
 
5.2.22 3’,5’-TBDMS-protected benzoxypyrimidine nucleoside (37) 
 
To 26 (0.07 g, 0.13 mmol) in 5 ml dry benzyl alcohol under Ar, NaOBn (1 M in benzyl alco-
hol, 0.75 ml, 0.75 mmol) was added dropwise by syringe. It was stirred for 2.5 h at 70 °C, 
then CH2Cl2 was added. The org. phase was washed with H2O, dried over Na2SO4 and evapo-
rated under reduced pressure. It was dried at the HV at 60 °C overnight. CC (SiO2, hex-
ane/EtOAc 3:1) gave 37 (0.04 g, 58 %) as a colourless oil. 
 
Rf (SiO2, hexane/EtOAc 3:1): 0.33 
1
H-NMR (300 MHz, CDCl3): ! 8.40 (d, J = 5.0 Hz, 1 H, HC(6), 37-"/#), 7.51-7.30 (m, 5 H, 
arom. H (Bn) 37-"/#), 6.93 (d, J = 5.0 Hz, 1 H, HC(5), 37-#), 6.90 (d, J = 5.0 Hz, 1 H, 37-"), 
5.44 (s, 2 H, H2COC(2), 37-"/#), 4.61-4.52 (m, 1 H, HC(1’), 37-"/#), 4.36 (dt, J = 6.1, 3.6 
Hz, HC(3’), 37-"), 4.29 (dt, J = 5.4, 1.9 Hz, 1 H, 37-#), 3.92 (dt, J = 5.1, 3.6 Hz, 1 H, HC(4’), 
37-"), 3.64 (ddd, J = 5.9, 3.9, 2.0 Hz, 1 H, HC(4’), 37-#), 3.64-3.39 (m, 2 H, H2C(5’), 37-
"/#), 3.16 (dd, J = 13.7, 7.9 Hz, 2 H, HCC(4), 37-"), 2.92 (m , 2 H, HCC(4), 37-#), 2.27-1.68 
(m, 2 H, H2C(2’), 37-"/#), 0.91, 0.88 (2 d, J = 1.7 Hz, 18 H, (H3C)3CSi, 37-"/#), 0.08-0.03 
(m, 12 H, (H3C)2Si, 37-"/#). 
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5.2.23 4-((2'-deoxy-!/"-D-ribofurano-1-yl)methyl)pyrimidin-2-one (36) 
 
37 (0.04 g, 0.08 mmol) was solved in 4.8 ml dry CH2Cl2 under Ar and it was cooled to 0 °C. 
BBr3 (1 M in CH2Cl2, 0.45 ml, 0.45 mmol) was added dropwise and it was stirred for 3 min at 
0 °C. 3 ml H2O were added, followed by 1 ml sat. NaHCO3 solution. It was separated and the 
water phase was evaporated under reduced pressure. Purification by CC (SiO2, EtOAc/MeOH 
1:1) afforded 36 (0.004 g, 24 %) as a light yellow solid. 
 
ESI-MS:  249.22 (75, [M+Na]+). 
 
5.2.24 2-deoxy-1-O-methyl-3,5-di-O-p-toluoyl-D-ribofuranose (38) 
 
2 (2.65 g, 17.87 mmol) was solved in 20 ml dry pyridine under Ar and cooled to 0 °C. p-
Toluoyl chloride (5.6 ml, 6.11 g, 39.49 mmol) was added dropwise by syringe. It was stirred 
overnight at RT. The reaction mixture was diluted with cold water and extracted 3 times with 
Et2O. The combined org. layers were washed with sat. NaHCO3 solution, H2O and sat. NaCl 
solution. It was dried over Na2SO4 and evaporated. CC (SiO2, Hex/EtOAc 2:1) afforded 38 
(5.72 g, 83 %) as a white solid in an anomeric mixture. 
 
Rf (SiO2, Hex/EtOAc 3:1): 0.49 
IR (film): 2952w, 2925w, 1718m, 1611w, 1445w, 1376w, 1270m, 1209w, 1177w, 1104w, 
1067w, 1020w, 753w. 
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1
H-NMR (300 MHz, CDCl3): ! 7.92-7.83 (m, 4 H, Ar-H), 7.19-7.13 (m, 4 H, Ar-H), 5.55-
5.32 (m, 1 H, HC(3)), 5.15 (td, J = 7.5, 2.8 Hz, 1 H, HC(1)), 4.58-4.38 (m, 3 H, HC(5) and 
HC(4)), 3.42, 3.36 (2 s, 2 H, "/#-OCH3), 2.49 (ddd, J = 14.1, 7.3, 2.2 Hz, 1 H, HC(2)), 2.41, 
2.39 (2 s, 2 H, "/#-CH3), 2.12 (ddd, J = 14.6, 2.2, 0.9 Hz, 1 H, HC(2)). 
13
C NMR (75 MHz, CDCl3): ! 166.3 (CO, "-38), 166.1 (CO, #-38), 144.0, 143.7 (Cipso 
(Tol)), 129.8, 129.7, 129.1, 129.1 (Cortho, Cmeta (Tol)), 127.2, 126.9 (Cpara (Tol)), 105.6 (C(1), 
#-38), 105.1 (C(1), "-38), 81.9 (C(4), #-38), 81.0 (C(4), "-38), 75.4 (C(3), #-38), 74.6 (C(3), 
"-38), 65.2 (C(5), #-38), 64.3 (C(5), "-38), 55.2 (OCH3, #-38), 55.1 (OCH3, "-38), 39.3 
(C(2), "/#-38), 21.7 (CH3 (Tol), "/#-38). 
ESI-MS: 407.2 (100, [M+Na]+). 
 
5.2.25 Toluoylprotected chlorosugar (39) 
 
A HCl solution was prepared by dropwise addition of acetyl chloride (0.88 ml, 0.96 g, 12.27 
mmol) to 4.05 ml acetic acid and 0.2 ml H2O at 0 °C. 4.5 ml of this HCl solution was added 
dropwise to 38 (1.71 g, 4.43 mmol) in 3.5 ml acetic acid at rt. Then, it was cooled to 0 °C and 
an additional amount of acetyl chloride (0.2 ml, 0.22 g, 2.80 mmol) was added. The formed 
precipitate was filtered and washed with cold Et2O. Drying at the HV overnight gave 39 
(1.30 g, 75 %) as a white solid. 
 
M.p.: 108.2 - 108.8 °C. 
IR (film): 1718s, 1682s, 1612m, 1577w, 1420m, 1377w, 1273s, 1178m, 1107m, 1020w, 959w, 
839w, 753s, 690w, 465w. 
1
H-NMR (300 MHz, CDCl3):  ! 7.99 (d, J = 8.2 Hz, 2 H, arom. H), 7.90 (d, J = 8.2 Hz, 2 H, 
arom. H), 7.28-7.23 (m, 4 H, arom. H), 6.48 (d, J = 4.9 Hz, 1 H, HC(1)), 5.52 (ddd, J = 7.3, 
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2.9, 1.2 Hz, 1 H, HC(3)), 4.86 (q, J = 3.6 Hz, 1 H, HC(4)), 4.74-4.61 (m, 2 H, H2C(5)), 2.94-
2.76 (m, 2 H, H2C(2)), 2.43, 2.42 (2 s, 6 H, H3CPh). 
13
C-NMR (75 MHz, CDCl3): ! 166.4, 166.4 (C=O), 144.3, 144.1 (Cipso (Tol)), 129.9, 129.7, 
129.3, 129.2 (Cortho, Cmeta (Tol)), 127.5, 127.3 (Cpara (Tol)), 95.4 (C(4)), 84.8 (C(3)), 72.9 
(C(1)), 63.7 (C(5)), 44.2 (C(2)), 21.7, 21.6 (CH3 (Tol)). 
 
5.2.26 Toluoylprotected cyanoribose (40) 
 
To 39 (3.60 g, 9.25 mmol) in 50 ml dry CH2Cl2 under Ar, TMS-CN (1.26 g, 12.68 mmol) and 
BF3-Et2O (2.38 g, 16.78 mmol) were added and it was stirred overnight at rt. 50 ml sat. 
NaHCO3 solution was added, it was separated and the water phase was extracted twice with 
EtOAc. The org. phases were dried over Na2SO4, evaporated under reduced pressure and puri-
fied by CC (SiO2, hexane/EtOAc 6:1 to 3:1) to give pure "-anomer 40 (1.87 g, 53 %) as a 
white solid and 40"  (0.39 g, 11 %) as a side product. 
 
40" 
Rf (SiO2, hexane/EtOAc/ 6:1): 0.49 
M.p.: 140.4 - 143.0 °C. 
IR: 1715s, 1611m, 1450w, 1409w, 1379w, 1266s, 1177m, 1102s, 1019m, 979w, 841w, 751s, 
690w, 573w. 
1
H-NMR (400 MHz, CDCl3): ! 7.97 (d, J = 8.2 Hz, 2 H, arom. H), 7.89 (d, J = 8.2 Hz, 2 H, 
arom. H), 7.26-7.24 (m, 4 H, arom. H), 5.60 (d, J = 5.8 Hz, 1 H, HC(3)), 4.91 (dd, J = 9.1, 6.7 
Hz, 1 H, HC(1)), 4.62-4.52 (m, 3 H, HC(4), H2C(5)), 2.77-2.61 (m, 2 H, H2C(2)), 2.42, 2.41 
(2 s, 6 H, H3C (Tol)). 
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13
C-NMR (100 MHz, CDCl3): ! 166.4, 165.9 (C=O), 144.8, 144.4 (Cipso (Tol)), 130.0, 129.9, 
129.5, 129.5 (Cortho, Cmeta (Tol)), 126.9, 126.5 (Cpara (Tol)), 118.1 (CN), 84.1 (C(4)), 75.6 
(C(3)), 66.1 (C(1)), 64.0 (C(5)), 38.1 (C(2)), 21.9, 21.9 (CH3 (Tol)). 
ESI-MS: 380.26 (100, [M+H]+). 
 
40!: 
Rf (SiO2, hexane/EtOAc/ 6:1): 0.46 
1
H-NMR (400 MHz, CDCl3):  ! 8.04 (d, J = 8.2 Hz, 2 H, arom. H), 7.94 (d, J = 8.2 Hz, 2 H, 
arom. H), 7.31-7.27 (m, 4 H, arom. H), 5.66-5.64 (m, 1 H, HC(3)), 5.08 (dd, J = 8.2, 1.6 Hz, 1 
H, HC(1)), 4.71 (td, J = 4.1, 2.0 Hz, 1 H, HC(4)), 4.57 (qd, J = 11.9, 4.1 Hz, 2 H, H2C(5)), 
2.73 (ddd, J = 14.3, 8.2, 6.0 Hz, 1 H, HC(2)), 2.63 (dt, J = 14.3, 1.4 Hz, 1 H, HC(2)), 2.45, 
2.44 (2 s, 6 H, H3C (Tol)). 
13
C-NMR (100 MHz, CDCl3): ! 166.25, 166.23 (C=O), 144.7, 144.4 (Cipso (Tol)), 130.2, 
129.9, 129.53, 129.47 (Cortho, Cmeta (Tol)), 126.9, 126.5 (Cpara (Tol), 118.7 (CN), 84.5 (C(4)), 
75.1 (C(3)), 66.7 (C(1)), 63.8 (C(5)), 38.1 (C(2)), 21.9, 21.9 (CH3 (Tol)). 
 
5.2.27 Toluoylprotected carboxylic acid ribose (41) 
 
To 40#  (1.18 g, 3.11 mmol) in 25 ml 1,4-dioxane was added 2.7 ml of 32% HCl and it was 
refluxed for 6 h. H2O was added and it was extracted twice with CH2Cl2 dried over MgSO4 
and evaporated. It was continued without further purification. 
 
IR (film): 3192w, 2952w, 1716s, 1611m, 1445w, 1376w, 1269s, 1177m, 1101s, 1020m, 840w, 
752s, 690w, 477w.  
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1
H-NMR (400 MHz, CDCl3):  ! 7.95-7.91 (m, 4 H, arom. H), 7.28-7.23 (m, 4 H, arom. H), 
5.52 (dd, J = 4.4, 1.5 Hz, 1 H, HC(3)), 4.82 (dd, J = 9.9, 6.6 Hz, 1 H, HC(1)), 4.65 (dd, J = 
12.7, 6.0 Hz, 1 H, HC(4)), 4.60-4.55 (m, 2 H, H2C(5)), 2.66 (ddd, J = 14.0, 6.7, 1.8 Hz, 1 H, 
H2C(2)), 2.48-2.45 (m, 1 H, H2C(2)), 2.43, 2.40 (2 s, H3C (Tol)). 
13
C-NMR (125 MHz, CDCl3): ! 173.0 (COOH), 167.2, 166.4 (C=O), 144.8, 144.6 (Cipso 
(Tol)), 130.1, 130.0, 129.5, 129.5 (Cortho, Cmeta (Tol)), 126.8, 126.6 (Cpara (Tol)), 84.9 (C(4)), 
75.7 (C(3)), 67.3 (C(1)), 64.6 (C(5)), 36.6 (C(2)), 22.0, 21.9 (CH3 (Tol)). 
ESI-MS: 397.26 (100, [M-H]-). 
 
5.2.28 Toluoylprotected methylhydroxy ribose(42) 
 
To crude 13 (1.48 g, 3.71 mmol) in 30 ml dry THF, BH3(Me)2S-complex (2 M, 3.0 ml, 5.79 
mmol) was added at 0 °C. It was stirred for 16 h at rt under Ar. H2O was added and it was 
extracted twice with CH2Cl2. The org. phase was washed with H2O and sat. NaCl solution, 
dried over MgSO4 and evaporated. CC (SiO2, hexane/EtOAc 2:1) afforded 42 (0.69 g, 58 % 
over two steps) as a colourless oil. 
 
Rf (SiO2, hexane/EtOAc 2:1): 0.24 
IR (film): 3484w, 2921w, 2877w, 1715m, 1611w, 1377w, 1269s, 1177m, 1105s, 1020m, 
960w, 841w, 752s, 690w. 
1
H-NMR (400 MHz, CDCl3): ! 7.94-7.89 (m, 4 H, arom. H), 7.26-7.22 (m, 4 H, arom. H), 
5.50 (d, J = 6.3 Hz, 1 H, HC(3)), 4.63-4.59 (m, 1 H, HC(1)), 4.49-4.42 (m, 3 H, HC(4) and 
H2C(5)), 3.91 (dd, J = 12.2 Hz, 2.8 Hz, 1 H, H2COH), 3.56 (dd, J = 12.2, 3.2 Hz, 1 H, 
H2COH), 2.42-2.37 (m, 1 H, H2C(2)), 2.42, 2.41 (2 s, 6 H, H3C (Tol)), 2.14 (dd, J = 5.6, 1.2 
Hz, 1 H, H2C(2)). 
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13
C-NMR (125 MHz, CDCl3): ! 167.0, 166.4 (C=O), 144.3, 144.2 (Cipso (Tol)), 130.0, 129.9, 
129.4, 129.3 (Cortho, Cmeta (Tol)), 127.2, 127.1 (Cpara (Tol)), 83.3 (C(4)); 80.2 (C(3)); 77.3 
(C(1)); 64.9 (C(5)); 63.2 (CH2OH); 33.4 (C(2)); 21.9, 21.8 (CH3 (Tol)). 
ESI-MS: 385.16 (40, [M+H]+), 407.13 (100, [M+Na]+). 
 
5.2.29 Toluoylprotected bromomethyl ribose (43) 
 
CBr4 (2.13 g, 6.43 mmol) and PPh3 (1.96 g, 7.47 mmol) were added to 42 (0.69 g, 1.79 mmol) 
in 10 ml dry CH2Cl2 at 0 °C under Ar. It was stirred for 1 h at rt. Then, the solvents were ev-
aporated under reduced pressure. It was purified by CC (SiO2, hexane/EtOAc 1:1) to give 43 
(0.74 g, 93 %) as a viscous oil. 
 
Rf (SiO2, hexane/EtOAc 1:1): 0.67 
 
IR (film): 2952w, 2922w, 1714s, 1611m, 1442w, 1408w, 1375w, 1266s, 1176m, 1099s, 
1020m, 923w, 840w, 751s, 690w, 476w. 
1
H-NMR (300 MHz, CDCl3): ! 7.94, 7.93 (2 d, J = 6.2 Hz, 4 H, arom. H), 7.26-7.23 (m, 4 H, 
arom. H), 5.55-5.53 (m, 1 H, HC(3)), 4.52-4.47 (m, 4 H, HC(1), HC(4), H2C(5)), 3.53-3.49 
(m, 2 H, CH2Br), 2.42, 2.41 (2 s, 6 H, H3C Tol)), 2.35 (ddd, J = 13.8, 5.4, 1.4 Hz, 1 H, 
H2C(2)), 2.20 (ddd, J = 13.8, 9.8, 6.2 Hz, 1 H, H2C(2’)). 
13
C-NMR (125 MHz, CDCl3): ! 166.5, 166.3 (C=O), 144.3, 144.1 (Cipso (Tol)), 130.1, 129.5 
(Cortho, Cmeta (Tol)), 127.3, 127.1 (Cpara (Tol)), 83.6 (C(4)), 78.4 (C(3)), 76.7 (C(1)), 64.8 
(C(5)), 37.7 (CH2Br), 34.5 (C(2)), 21.9, 21.8 (CH3 (Tol)). 
ESI-MS: 447.19 (98, [M+H]+), 449.19 (100, [M+H]+). 
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5.2.30 Toluoylprotected methylxanthate ribose (44) 
 
To 43 (0.06 g, 0.13 mmol) in 2 ml dry acetone under Ar, potassium ethyl xanthogenate (0.06 
g, 0.39 mmol) was added and it was refluxed for 2 h. The solvent was eyaporated and it was 
dissolved in CH2Cl2. The organic layer was washed with water, sat. NaCl solution and dried 
over Na2SO4. CC (SiO2, hexane to hexane/EtOAc 3:1) afforded 44 (0.04 g, 60 %) as a colour-
less oil. 
 
Rf (SiO2, hexane/EtOAc 1:1): 0.66 
IR (film): 2954w, 2921w, 1715s, 1611m, 1508w, 1448w, 1408w, 1374w, 1266s, 1212m, 
1176m, 1100s, 1045s, 1019s, 922w, 840m, 751s, 690m, 607w.  
1
H-NMR (500 MHz, CDCl3): ! 7.96-7.91 (m, 4 H, arom. H), 7.26-7.23 (m, 4 H, arom. H), 
5.50 (d, J = 6.1 Hz, 1 H, HC(3)), 4.66-4.62 (m, HC(1)), 4.55-4.39 (m, 3 H, HC(4), H2C(5)), 
3.55-3.47 (m, H2CS), 2.42, 2.41 (2 s, 6 H, H3C (Tol)), 2.38-2.09 (m, 2 H, H2C(2)), 1.41 (t, J = 
7.1 Hz, 3 H, H3CH2CO), 1.28-1.24 (m, 2 H, H3CH2CO). 
13
C-NMR (125 MHz, CDCl3): ! 214.7 (CSO), 166.5, 166.2, (C=O), 144.4, 144.1 (Cipso (Tol)); 
130.0, 129.4 (Cortho, Cmeta (Tol)), 127.3, 127.1 (Cpara (Tol)), 83.3 (C(4)), 77.4 (C(3)), 70.6 
(C(1)), 64.6 (C(5)), 40.1 (CH3CH2O), 37.7 (CH2SCSO), 34.5 (C(2)), 21.9, 21.9 (CH3 Tol)), 
14.0 (CH3CH2O). 
ESI-MS: 489.37 (100, [M+H]+), 511.45 (7, [M+Na]+). 
 
5.2.31 1,2-dideoxy-3,5-di-O-(p-toluyl)-d-ribofuranose (47) 
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To a solution of 38 (3.15 g, 8.20 mmol) in 20 ml dry CH2Cl2 at 0 °C under Ar, triethylsilane 
(2.9 ml, 2.12 g, 18.21 mmol) and BF3-etherate (2.3 ml, 2.60 g, 18.31 mmol) were added by 
syringe. It was stirred for 1 h at 0 °C, then it was let warm to rt and stirred for 30 min. Sat. 
NaHCO3 solution was added and it was stirred vigorously for 10 min. H2O and CH2Cl2 were 
added and it was separated. The water phase was washed twice with CH2Cl2. The combined 
organic layers were dried over Na2SO4, filtered and the solvents were evaporated under re-
duced pressure. CC (SiO2, Hex/Et2O 1:1) afforded 47 (2.50 g, 86 %) as a bright yellow oil. 
 
Rf (SiO2, Hex/Et2O 1:1): 0.47 
IR (film): 2952w, 1715s, 1611m, 1508w, 1454w, 1408w, 1376w, 1268s, 1209w, 1177m, 
1099s, 1020w, 840w, 752s, 690w.  
1
H-NMR (300 MHz, CDCl3): ! 7.95-7.91 (m, 4 H, arom. H), 7.26-7.21 (m, 4 H, arom. H), 
5.47 (td, J = 4.3, 2.1 Hz, 1 H, HC(3)), 4.49 (td, J = 4.3, 2.1 Hz, 2 H, HC(5)), 4.37 (td, J = 4.6, 
2.4 Hz, 1 H, HC(4)), 4.20-4.00 (m, 2 H, HC(1)), 2.41 (2 s, 6 H, 2 H3C), 2.37-2.15 (m, 2 H, 
HC(2)). 
13
C NMR (75 MHz, CDCl3): ! 166.35, 166.22 (CO), 144.0, 143.8 (Cipso (Tol)), 129.8, 129.7, 
129.1, 129.1 (Cortho, Cmeta (Tol)), 127.1, 127.0 (Cpara (Tol)), 82.2 (C(4)), 76.5 (C(3)), 67.8 
(C(1)), 64.6 (C(5)), 32.9 (C(2)), 21.7, 21.6 (CH3 (Tol)). 
 
5.2.32 1,2-dideoxy-D-ribofuranose (48) 
 
NaOMe (0.03 g, 0.58 mmol) in 10 ml MeOH was added to 47 (0.17 g, 0.48 mmol) under Ar 
and it was stirred for 7 h at RT. The solvent was evaporated and it was purified by CC (SiO2, 
EtOAc/MeOH 20:1) to obtain 48 (0.07 g, 80 %). 
 
Rf (SiO2, CH2Cl2/MeOH 9:1): 0.33 
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1
H-NMR (300 MHz, DMSO-d6): ! 4.86 (d, J = 4.1 Hz, 1 H, HOC(3)), 4.62 (t, J = 5.7 Hz, 1 
H, HOC(5)), 4.06-4.02 (m, 1 H, HC(3)), 3.78-3.71 (m, 2 H, HC(1)), 3.56 (td, J = 5.3, 2.9 Hz, 
1 H, HC(4)), 3.35-3.29 (m, 2 H, HC(5)), 1.94-1.85 (m, 1 H, HC(2)), 1.72-1.65 (m, 1 H, 
HC(2)). 
13
C-NMR (75.5 MHz, MeOH-d4): !  88.4 (C(4)), 74.1 (C(3)), 68.6 (C(1)), 64.1 (C(5)), 36.0 
(C(2)). 
 
5.2.33 1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-D-ribofuranose (49) 
 
4-(dimethylamino)pyridine (0.01, 0.09 mmol) and DMTCl (0.31 g, 0.90 mmol) were both 
dried at the HV overnight, then solved in 5 ml dry pyridine under Ar. NEt(iPr)2 (0.13 ml, 0.10 
g, 0.75 mmol) and 48 (0.06 g, 0.50 mmol) in 1 ml dry pyridine were added. It was stirred for 
20 h at RT under Ar. The solvent was evaporated and the residue was resolved in CH2Cl2 con-
taining 1 % TEA. It was washed with sat. NaHCO3 solution, H2O and sat. NaCl solution, 
dried over Na2SO4 and evaporated. CC (SiO2, CH2Cl2/EtOAc/TEA 75:14:1) afforded 49 (0.06 
g, 44 %). 
 
Rf (SiO2, CH2Cl2/EtOAc/TEA 75:14:1): 0.37 
1
H-NMR (300 MHz, CDCl3): ! 7.44-6.81 (m, 13 H, arom. H), !  4.31-4.27 (m, 1 H, HC(3)), 
3.97 (dd, J = 8.3, 5.6 Hz, 2 H, H2C(1)), 3.90-3.87 (m, 1 H, HC(4)), 3.80, 3.79 (2 s, 6 H, 
H3CO), 3.25-3.10 (m, 2 H, H2C(5)), 2.15-1.86 (m, 2 H, H2C(2)). 
13
C-NMR (75.5 MHz, CDCl3): ! 158.5 (Cpara (PhOMe)), 146.8 (Cipso (Ph)), 136.0 (Cipso 
(PhOMe)), 130.1 (Cortho (PhOMe)), 128.1, 127.8 (Cortho (Ph), Cmeta (Ph)), 126.8 (Cpara (Ph)), 
113.1 (Cmeta, (PhOMe), 86.1 (Ctert (Tr)), 85.0 (C(4)), 74.5 (C(3)), 67.1 (C(1)), 64.9 (C(5)), 
55.2 (CH3O), 34.9 (C(2)). 
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5.2.34 (1,2-dideoxy-5-O-(4,4'-dimethoxytrityl)-D-ribofuranoyl)-"-cyanoethyl-N,N-
diisopropyl phosphoramidite (50) 
 
To 49 (0.05 g, 0.12 mmol) in 0.3 ml dry CH2Cl2 under Ar, PCl(N(iPr)2OEtCN)) (0.05 g, 0.20 
mmol) in 1 ml dry pyridine and NEt(iPr)2 (0.07 ml, 0.05 g, 0.41 mmol) were added. It was 
stirred for 2 h at RT, then MeOH was added. EtOAc containing 1 % TEA was added and it 
was washed with sat. NaHCO3 solution, H2O and sat. NaCl solution, dried over Na2SO4 and 
evaporated. CC (SiO2, CH2Cl2/EtOAc/TEA 45:45:10) afforded 50 (0.06 g, 83 %) as a viscous 
oil. 
 
Rf (SiO2, CH2Cl2/EtOAc/TEA 45:45:10): 0.83 
IR (film): 2965w, 1607m, 1508s, 1463w, 1395w, 1363w, 1300w, 1249s, 1176m, 1155w, 
1061m, 1033s, 975m, 914m, 876w, 828m, 791w, 727m, 703m, 644w, 584m, 525w. 
1
H-NMR (300 MHz, CDCl3): ! 7.46-7.42 (m, 1 H, HCpara (Ph)), 7.35-7.19 (m, 8 H, HCortho 
(PhOMe), HCortho (Ph), HCmeta (Ph)), 6.84-6.80 (m, 4 H, HCmeta (PhOMe)), 4.45-4.36 (m, 1 H, 
HC(3)), 4.07-4.00 (m, 3 H H2C(1), HC(4)), 3.79, 3.78 (2 s, 6 H, H3CO), 3.70-3.53 (m, 4 H, 
H2C(5), OCH2CH2CN), 3.16-3.09 (m, 2 H, NCHMe2), 2.59, 2.44 (2 t, J = 6.5 Hz, 2 H, 
OCH2CH2CN), 2.17-1.93 (m, 2 H, H2C(2)), 1.28-1.06 (m, 12 H, ((CH3)2CH)2N). 
13
C-NMR (75.5 MHz, CDCl3): ! 158.4 (Cpara (PhOMe)), 144.9 (Cipso (Ph)), 136.1 (Cipso 
(PhOMe)), 130.1 (Cortho (PhOMe)), 128.3, 127.8 (Cortho (Ph), Cmeta (Ph)), 126.7 (Cpara (Ph)), 
117.6 (CN), 113.1 (Cmeta, (PhOMe), 86.0 (Ctert (Tr)), 84.9 (C(4)), 74.6 (C(3)), 67.5 (C(1)), 
64.2 (C(5)), 58.3 (OCH2CH2CN), 55.2 (CH3O), 43.2 (NCHMe2), 34.4 (C(2)), 24.6, 24.5 
((CH3)2CH)2N), 20.2 (OCH2CH2CN). 
31
P-NMR (161 MHz, CDCl3): ! 149.1, 148.8. 
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5.2.35 3’,5’-p-Bromobenzoyl protected 2-thiomethylpyrimidine nucleoside (52) 
 
To 4-bromobenzoyl chloride (0.48 g, 2.13 mmol) at 0 °C, 51 (0.60 g, 2.30 mmol) in 2.2 ml 
dry pyridine was added under Ar. It was stirred for 16 h at rt, then EtOAc was added and it 
was washed once with 5 % HCl solution in H2O and twice with H2O. It was dried over 
Na2SO4 and evaporated under reduced pressure. CC (SiO2, hexane/EtOAc 2:1) afforded 52 
(0.28 g, 52 %) as a bright yellow waxlike solid. 
 
Rf (SiO2, Hexan/EtOAc 2:1): 0.52 
1
H-NMR (500 MHz, CDCl3): ! 8.41 (d, J = 5.0 Hz, 1 H, HC(6), "-52), 8.38 (d, J = 5.0 Hz, 1 
H, HC(6), #-52), 7.89 (d, 4 H, J = 8.5 Hz, arom. Hortho, "/#-52), 7.60 (dd, J = 8.5, 2.5 Hz, 4 H, 
arom. Hmeta, "/#-52), 6.91 (d, J = 5.0 Hz, 1 H, HC(5), "/#-52), 5.51-5.48 (m, 1 H, HC(1’), 
"/#-52), 4.74 (t, J = 6.5 Hz, 1 H, HC(3’), "-52), 4.64 (dt, J = 10.9, 5.4 Hz, 1 H, HC(3’), #-
52), 4.56-4.46 (m, 2 H, H2C(5’), "/#-52), 4.35-4.33 (m, 1 H, HC(4’), "/#-52), 3.15 (d, J = 7.2 
Hz, 1 H, HCC(4), "-52), 3.00 (dd, J = 5.7, 2.2 Hz, 2 H, H2CC(4), #-52), 2.67 (d, J = 7.0 Hz, 1 
H, HCC(4), "-52), 2.56 (s, 3 H, H3CS, #-52), 2.54 (s, 3 H, H3CS, "-52), 2.34 (dd, J = 13.9, 
4.9 Hz, 1 H, HC(2’), "/#-52), 2.15 (dt, J = 9.3, 4.5 Hz, 1 H, HC(2’), "-52), 2.07 (ddd, J = 
13.9, 10.6, 6.4 Hz, 1 H, HC(2’), #-52). 
13
C-NMR (125 MHz, CDCl3): ! 172.5 (C(2), "-52), 172.4 (C(2), #-52), 167.0, 166.8 (CO, 
"/#-52), 165.6 (C(4), "-52), 165.5 (C(4), #-52), 165.4 (arom. Cipso, "-52), 165.3 (arom. Cipso, 
#-52), 157.0 (C(6), "-52), 156.9 (C(6), #-52), 131.9, 131.8, 131.2, 131.1 (Cortho, Cmeta (Tol), 
"/#-52), 128.7, 128.6 (Cpara (Tol), "-52), 128.5, 128.4 (Cpara (Tol), #-52), 116.6 (C(5), #-52), 
116.3 (C(5), "-52), 82.5 (C(4’), #-52), 81.6 (C(4’), "-52), 77.8 (C(3’), "-52), 77.7 (C(3’), #-
52), 77.2 (C(1’), "-52), 77.1 (C(1’), #-52), 64.8 (C(5’), #-52), 64.7 (C(5’), "-52), 43.7 
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(CC(4), "-52), 42.9 (CC(4), #-52), 38.3 (C(2’), #-52), 37.2 (C(2’), "-52), 14.1 (SCH3, #-52), 
14.1 (SCH3, "-52). 
ESI-MS: 645.26 (100, [M+Na]+). 
 
5.2.36 3’,5’-p-Nitrobenzoyl protected 2-thiomethylpyrimidine nucleoside (53) 
 
To 4-nitrobenzoyl chloride (0.07 g, 0.52 mmol) in 0.4 ml dry pyridine at 0 °C, 51 (0.06 g, 
0.25 mmol) in 0.4 ml dry pyridine was added under Ar. It was stirred for 16 h at rt, then 
EtOAc was added and it was washed once with 5 % HCl solution in H2O and twice with H2O. 
It was dried over Na2SO4 and evaporated under reduced pressure. CC (SiO2, hexane/EtOAc 
2:1) afforded 53 (0.07 g, 51 %) as a colourless viscous oil. 
 
Rf (SiO2, Hexan/EtOAc 2:1): 0.23 
1
H-NMR (500 MHz, CDCl3): ! 8.35 (d, J = 5.0 Hz, 1 H, HC(6), "-53), 8.31 (d, J = 5.0 Hz, 1 
H, HC(6), #-53), 8.26-8.11 (m, 8 H, arom. H, "/#-53), 6.84 (d, J = 5.0 Hz, 1 H, HC(5), "/#-
53), 5.45 (d, J = 6.4 Hz, 1 H, HC(1’), "/#-53), 4.71-4.64 (m, 1 H, HC(3), "-53), 4.60 (dt, J = 
10.9, 5.5 Hz, 1 H, HC(3’), #-53), 4.52-4.43 (m, 2 H, H2C(5’), "/#-53), 4.29 (td, J = 4.6, 2.1 
Hz, 1 H, HC(4’), "/#-53), 3.08 (dd, J = 14.0, 7.1 Hz, 1 H, HCC(4), "-53), 2.97-2.94 (m, 2 H, 
H2CC(4), #-53), 2.63 (dd, J = 14.1, 7.1 Hz, 1 H, HCC(4), "-53), 2.47 (s, 3 H, H3C, #-53), 
2.46 (s, 3 H, H3C, "-53), 2.32 (dd, J = 14.2, 5.0 Hz, 1 H, HC(2’), "/#-53), 2.17-2.10 (m, 1 H, 
HC(2), "-53), 2.03 (ddd, J = 14.0, 10.7, 6.4 Hz, 1 H, HC(2), #-53). 
13
C-NMR (125 MHz, CDCl3): ! 172.5 (C(2), "-53), 172.4 (C(2), #-53), 166.7, 166.6 (CO, 
"/#-53), 164. 3 (C(4), #-53), 164.2 (C(4), "-53), 157.0 (C(6), "-53), 156.9 (C(6), #-53), 
150.9, 150.8 (arom. Cpara, "/#-53), 135.1, 134.8 (arom. Cipso, "/#-53), 130.9, 130.8 (arom. 
Cortho, "/#-53), 123.6, 123.7 (arom. Cmeta, "/#-53), 116.6 (C(5), #-53), 116.3 (C(5), "-53), 
5. Experimental Part 
 
 
 117 
82.4 (C(4’), #-53), 81.5 (C(4’), "-53), 77.9 (C(3’), "-53), 77.8 (C(3’), #-53), 77.4 (C(1’), "-
53), 77.2 (C(1’), #-53), 65.3 (C(5’), "/#-53), 43.5 (CC(4), "-53), 42.7 (CC(4), #-53), 38.1 
(C(2’), #-53), 37.1 (C(2’), "-53), 14.1 (SCH3, #-53), 14.1 (SCH3, "-53). 
ESI-MS: 555.54 (100, [M+H]+). 
 
5.2.37 3’,5’-Naphtoyl protected 2-thiomethylpyrimidine nucleoside (54) 
 
To 2-naphtoyl chloride (0.29 g, 1.52 mmol) in 1 ml dry pyridine at 0 °C, 51 (0.16 g, 0.61 
mmol) in 1 ml dry pyridine was added under Ar. It was stirred for 16 h at rt, then EtOAc was 
added and it was washed once with 5 % HCl solution in H2O and twice with H2O. It was dried 
over Na2SO4 and evaporated under reduced pressure. CC (SiO2, hexane/EtOAc 5:1) afforded 
54 (0.05 g, 15 %) as a waxlike solid. 
 
Rf (SiO2, Hexan/EtOAc 2:1): 0.55 
1
H-NMR (500 MHz, CDCl3): ! 9.08 (d, J = 8.7 Hz, 1 H, HC(6), "/#-54), 8.96-7.48 (m, 14 H, 
arom. H, "/#-54), 6.91 (d, J = 5.0 Hz, 1 H, HC(5), "/#-54), 5.64 (d, J = 6.1 Hz, 1 H, HC(1’), 
#-54), 5.48-5.47 (m, 1 H, HC(1’), "-54), 4.82-4.80 (m, 1 H, HC(3’), "-54), 4.72-4.64 (m, 3 
H, HC(3’), #-54 and H2C(5’), "/#-54), 4.51 (dd, J = 6.3, 4.2 Hz, 1 H, HC(4’), "/#-54), 3.18 
(dd, J = 7.2, 6.8 Hz, HCC(4), "-54), 3.05-2.98 (m, 2 H, H2CC(4), #-54), 2.76 (dd, J = 7.2, 6.8 
Hz, HCC(4), "-54), 2.53 (s, 3 H, H3CS, #-54), 2.50 (s, 3 H, H3CS, "-54), 2.40 (dd, J = 13.9, 
4.9 Hz, 1 H, HC(2’), "/#-54), 2.18-2.12 (m, 1 H, HC(2’), "/#-54). 
13
C-NMR (125 MHz, CDCl3): ! 172.4 (C(2), #-54), 171.8 (C(2), "-54), 167.2, 167.2 (CO, 
"/#-54), 167.1 (C(4), "-54), 167.0 (C(4), #-54), 157.0 (C(6), "-54), 156.9 (C(6), #-54), 
134.5, 133.9, 133.7, 131.7, 130.5, 130.3, 128.7, 128.7, 128.6, 128.1, 128.0, 127.9, 126.4, 
126.3, 126.0, 125.8, 125.6, 124.6, 124.5, 124.4 (arom. C (Naphtoyl), "/#-54), 116.6 (C(5), #-
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54), 116.4 (C(5), "-54), 82.8 (C(4’), #-54), 81.9 (C(4’), "-54), 77.9 (C(3’), #-54), 77.7 
(C(3’), "-54), 77.1 (C(1’), "-54), 77.0 (C(1’), #-54), 64.9 (C(5’), #-54), 64.8 (C(5’), "-54), 
43.8 (CC(4), "-54), 43.1 (CC(4), #-54), 38.6 (C(2’), #-54), 37.5 (C(2’), "-54), 14.1 (SCH3, #-
54), 14.0 (SCH3, "-54). 
ESI-MS: 565.57 (100, [M+H]+). 
 
5.2.38 3’,5’-Dimethylbenzoyl protected 2-thiomethylpyrimidine nucleoside (55) 
 
51 (0.22 g, 0.85 mmol) in 2.2 ml dry pyridine was added dropwise to dimethylbenzoyl chlori-
de (0.34 g, 1.79 mmol) at 0 °C under Ar. It was stirred for 16 h. EtOAc was added and it was 
washed once with 5 % HCl solution in H2O and twice with H2O, dried over Na2SO4 and eva-
porated under reduced pressure. After CC (SiO2, hexane/EtOAc 2:1), 55 (0.34 g, 77 %) was 
obtained as a waxlike solid. 
 
Rf (SiO2,  Hexan/EtOAc 2:1): 0.54 
1
H-NMR (500 MHz, CDCl3): ! 8.41 (d, J = 5.0 Hz, 1 H, HC(6), "-55), 8.37 (d, J = 5.0 Hz, 1 
H, #-55), 7.73-7.65 (m, 4 H, arom. Hmeta, "/#-55), 7.26-7.20 (m, 4 H, arom. Hortho, "/#-55), 
6.93 (d, J = 5.0 Hz, 1 H, HC(5), "/#-55), 5.52-5.50 (m, 1 H, HC(1’), "/#-55), 4.78-4.73 (m, 1 
H, HC(3’), "-55), 4.71-4.63 (m, 1 H, HC(3’), #-55), 4.59-4.45 (m, 2 H, H2C(5’), "/#-55), 
4.38 (td, J = 4.3, 2.2 Hz, 1 H, HC(4’), "/#-55), 3.18 (dd, J = 13.8, 7.3 Hz, 1 H, HCC(4), "-
55), 3.00 (d, J = 6.2 Hz, 2 H, H2CC(4), #-55), 2.70 (dt, J = 14.1, 7.1 Hz, 1 H, HC(4), "-55), 
2.56 (s, 3 H, H3CS, #-55), ), 2.54 (s, 3 H, H3CS, "-55), 2.40-2.39 (m, 1 H, HC(2’), "/#-55), 
2.37 (s, 12 H, H3C, #-55), 2.35 (s, 12 H, H3C, "-55), 2.16-2.08 (m, 1 H, HC(2’), "/#-55). 
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13
C-NMR (125 MHz, CDCl3): ! 172.5 (C(2), "-55), 172.4 (C(2), #-55), 167.2, 167.1 (CO, 
"/#-55), 166.6 (C(4), "-55), 166.5 (C(4), #-55), 157.0 (C(6), "-55), 156.9 (C(6), #-55), 
138.2, 138.1 (arom. Cipso, "/#-55), 135.0, 134.9 (arom. Cmeta, "/#-55), 129.7, 129.5 (arom. 
Cpara, "/#-55), 127.9, 127.4 (arom. Cortho, "/#-55), 116.6 (C(5), #-55), 116.3 (C(5), "-55), 
82.7 (C(4’), #-55), 81.6 (C(4’), "-55), 77.8 (C(3’), #-55), 77.7 (C(3’), "-55), 76.9 (C(1’), #-
55), 76.6 (C(1’), "-55), 64.6 (C(5’), #-55), 64.5 (C(5’), "-54), 43.8 (CC(4), "-55), 43.2 
(CC(4), #-55), 38.5 (C(2’), #-55), 37.5 (C(2’), "-55), 21.2, 21.1 (CH3, "/#-55), 14.1 (SCH3, 
"-55), 14.0 (SCH3, #-55). 
ESI-MS: 521.51 (100, [M+H]+), 543.57 (15, [M+Na]+). 
 
5.2.39 CE PA dU 
Cyanoethylphosphoramidite dU was synthesised in two steps from commercially available 2’-
deoxyuridine in good yields, according to well established literature procedures.111 
 
5.2.40 Oligonucleotide Synthesis 
Oligonucleotides were synthesised on a DNA-synthesiser (Expedite 8900, Applied Biosys-
tems) in 1.0 µmol scale using standard specifications and protocol for automated 3’%5’ syn-
thesis with following modifications: The phosphoramidite concentrations were reduced from 
0.1 M to 0.06 M. Furthermore, the more potent 5-(ethylthio)-1H-tetrazole was used as activa-
tor, instead of 1H-tetrazole. In addition, the coupling times for the artificial nucleotide dD as 
well as the abasic site were elongated from 90 sec to 12 min. Oligonucleotide syntheses were 
performed staring from commercially available nucleosides, bound to controlled pore glas 
(1000 Å) from Biosearch. The corresponding commercially available cyanoethyl phosphora-
midites were used for the insertion of dA, dG and dC. To release the synthesised oligonucleo-
tide strands from solid support and to chip all nucleobase and phosphate protecting groups, 
they were treated with oversaturated aq. NH3-solution at 50 °C for 20 h. Purification was 
achieved by RP-HPLC on a semi-preperative YMC basic column with a H2O-MeCN gradient. 
The oligonucleotides were analysed by MALDI-TOF-MS (Matrix: 3-HPA). The oligonucleo-
tide concentrations were determined by the Lambert-Beer law measuring the optical density 
at 260 nm. 
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